Latest News

Find Out What's New at Alternate Health.

ALTERNATE HEALTH OBTAINS CALIFORNIA CANNABIS DISTRIBUTION, MANUFACTURING AND CULTIVATION LICENSES THROUGH ACQUISITION

SAN ANTONIO, TX. October 17, 2018 – Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF)), an international leader in technology solutions for the regulated cannabis industry, announced today that the Company signed an arms length agreement on October 16, 2018, to acquire 100% of Four Twenty Inc., receiving coveted cannabis distribution, manufacturing, processing and cultivation permits as part of the agreement. Four Twenty Inc. also holds a five-year lease with an extension and purchase option on a 14,800 square foot, licensed facility in Humboldt County, California.

“With this acquisition, Alternate Health has the potential to take a leadership position in California’s cannabis industry,” says Dr. Murphy, Chairman and CEO of Alternate Health. “Based in the heart of Humboldt County, Four Twenty Inc. is strategically located giving Alternate Health the capacity to capture a dominant portion of the distribution market in one of the world’s most famous and well-respected cultivation areas.”

Four Twenty Inc. was established in 2015 by George Mull, a distinguished attorney and one of California’s foremost experts in the legal cannabis industry. Originally founded to provide consulting and legal advice for cannabis licensing and operations, Four Twenty Inc. has developed strong relationships with an extensive network of premiere cultivators throughout Humboldt County. These relationships form a key competitive advantage as Alternate Health and Four Twenty Inc. expand into cannabis distribution and product development.

Highlights of the Four Twenty Acquisition:

  • As part of the acquisition, Alternate Health will receive valid California distribution, manufacturing, processing and cultivation permits and licenses. The formal Request to Transfer permits/licenses to the Company’s designated subsidiary is expected to be processed by Humboldt County in less that 30 days.
  • Four Twenty Inc.’s lease is on a 14,800 square foot facility on nine acres in Humboldt County, fully licensed for commercial cannabis activity with plans to immediately commence operations.
  • The facility is strategically located in the heart of California’s Emerald Triangle, an award-winning growing region famous for AAA grade cannabis.
  • The agreement includes the Humboldt Ave. Cannabis label, with plans to immediately distribute Humboldt Ave. branded products across the state.
  • Four Twenty Inc. maintains professional relationships with the region’s top cultivators, providing expert legal advice and consulting services.
  • According to reporting in the San Francisco Chronicle, cannabis production contributes nearly $400 million* annually to the local economy. With its strategic location in Humboldt County, coupled with its extensive cultivator relationships, Alternate Health is well positioned to secure exclusive cannabis distribution contracts from this significant market.

Peter Fimrite: “Allure of Legal Weed is fueling a land rush in Emerald Triangle.” San Francisco Chronicle, May 27, 2016

Alternate Health plans on operating the Four Twenty Inc. subsidiary primarily as a distribution and packaging consulting company. Four Twenty Inc. will continue its management consulting and compliance advice activities with cultivators, but with a focus on incentivizing exclusive distribution deals. The manufacturing, processing, distribution and cultivation permits will be transferred to subsidiaries of Alternate Health. Alternate Health will earn revenues from associated distribution, processing, packaging and transport fees.

Alternate Health intends to establish retail distribution channels to dispensary partners in Los Angeles County. According U.S. Census Bureau data, the combined Los Angeles – Orange County metropolitan area has economy of over $1 trillion. Alternate Health recognizes the tremendous potential the Humboldt brand has among Los Angeles customers.

“Now is the perfect time to expand into California’s cannabis distribution market,” says Dr. Murphy. “The state’s cannabis regulations are just beginning to come into effect and, with our new permits and facility, we are well positioned to capture cannabis revenues as California phases out grey market sales.”

About Humboldt Ave. Cannabis

Alternate Health. is focused on growing the Humboldt Ave. brand, distributing high quality cannabis from Humboldt to dispensary partners in the Greater Los Angeles area. With hundreds of cultivators in Humboldt County, Four Twenty Inc. has provided Alternate Health with the network to supply high quality cannabis to the world’s most valuable cannabis market.

In an industry driven by quality, Humboldt Ave Cannabis enjoys the following benefits:

  • Other California producers focus on mass-market cannabis, but Humboldt County has a large, experienced cultivation community with a reputation for producing extremely high quality product.
  • Humboldt County’s artisan approach to cannabis cultivation appeals to knowledgeable customers who are willing to pay more for a premium product.
  • As stricter cannabis testing rules come into effect in 2019, Humboldt County’s expert cultivators already meet many standards, unlike much of the mass-market production.
  • Humboldt County cultivators prioritize organic and natural farming methods that resonate with environmentally conscious customers.

For more information on the Humboldt Ave. brand, visit www.HumboldtAve.com.

Terms of the Agreement

As consideration for the acquisition, Four Twenty Inc. founder, George Mull, will receive 1,000,000 warrants for common stock in Alternate Health Corp. The warrants have a five-year term with an exercise price per share of CDN$ 0.57. In addition, the Company is entering a management contract with George Mull or an entity controlled by George for a fee equal to 20% of net income, defined as revenue less all expenses from certain operations of Alternate Health to be mutually agreed.

About Alternate Health

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. Through its software solutions, data analytics, and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. For more information about Alternate Health Corp., visit www.alternatehealth.ca.

Investor Contact:

Jim Griffiths, Director

1.416.607.5757 | j.griffiths@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects, financing plans and spin off plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.


ALTERNATE HEALTH ANNOUNCES CLOSING FINAL TRANCHE OF PRIVATE PLACEMENT AND CHANGE IN OFFICER POSITIONS

SAN ANTONIO, TX. October 11, 2018 – Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF), an international leader in software solutions for the medical cannabis industry, is pleased to announce that it has closed the final tranche of a non-brokered private placement of 909,091 common shares at a price of CAD$0.43 (USD$0.33) per common share for aggregate gross proceeds of US$300,000. The first tranche in the amount of US$585,000 (1,772,726 shares) closed on August 28, 2018. The common shares are subject to a four month and one day hold period in accordance with Canadian securities laws.

“We are extremely pleased to have completed this private placement which will facilitate important expansion opportunities in our product distribution and CBD marketing businesses supported by our blockchain enabled payment software”, says Dr. Murphy, CEO of Alternate Health.

In addition to funding expansion opportunities in product distribution and CBD marketing, private placement proceeds will be used in Alternate Health’s CanaPass marketing and for general working capital purposes.

APPOINTMENT OF OFFICER

The Company wishes to announce the appointment of Stephen Bugbee as SVP, Technology. Stephen Bugbee is a technology consultant who specializes in sales, marketing, business development, management and operations in the technology sector. His proven track record in taking companies to profitability is second to none. Stephen initially worked with many large brands in the entertainment space at the inception of the Internet assisting companies like Carsey Werner, King World and the Coca Cola Company to embrace early rich media technologies. This was followed by helping Digital Island acquire Softaware, Sandpiper Networks and Exodus prior to preparing the company for the Cable and Wireless acquisition. For the past 15+ years Stephen has helped many companies reach heightened profitability by utilizing his experience and skill-set to Director manage and drive revenue.

For more information about Alternate Health, visit www.alternatehealth.com.

CESSATION OF OFFICER ROLE

The Company also wishes to announce that due to increasing commitments in other activities Ms. Jade Green is no longer serving in role of VP, Sales and Marketing of the Company. The Company would like to thank Jade for her assistance while serving as an Officer and looks forward to working with her in the future on a consultancy basis.

About Alternate Health

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. Through its software solutions, data analytics and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.ca.

Investor Contact:

Jim Griffiths, Director

1.416.607.5757 | j.griffiths@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects, financing plans and spin off plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.


ALTERNATE HEALTH LAUNCHES FIRST MEDICAL CANNABIS ONLINE SHOPPING PORTAL IN FLORIDA

SAN ANTONIO, TX. September 26, 2018 – Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF), an international leader in software solutions for the medical cannabis industry, announced today the launch of its FlorPass medical cannabis online shopping portal with Liberty Health Sciences in Florida.

“With the launch of the system’s e-commerce and digital transaction features, FlorPass is transforming how patients shop for their medical cannabis online,” says Dr. Michael Murphy, Chairman and CEO of Alternate Health. “As the only medical cannabis e-commerce system approved by the Florida Department of Health, we have established an innovative model with the ability to capture the statewide market for digital cannabis transactions.”

Alternate Health and Liberty Health Sciences gained approval from the Florida Department of Health in August to offer medical cannabis e-commerce features. The FlorPass online shopping portal has launched for certified patients in St. Petersburg and Tampa with plans to quickly expand to additional locations before the end of October.

“We are excited to be the first in Florida to provide FlorPass, a cutting edge, secure online shopping experience for our diverse collection of premium cannabis products,” said George Scorsis, CEO of Liberty Health Sciences. “This is not only a functional way to do transactions, FlorPass will help us grow our business by building better relationships with our patients and enhance overall patient satisfaction. We will continue to invest in state-of-the-art technology to support the development of our products and remain committed to providing guidance and continued care throughout the entire patient experience.”

Alternate Health anticipates strong revenue potential from FlorPass and is aggressively expanding its market presence throughout Florida. FlorPass is the first-mover for medical cannabis e-commerce in the state, following the activation of digital transaction capabilities, which positions the Company to take the lead in developing this promising market.

The FlorPass Electronic Medical Records (“EMR”) platform launched in clinics and doctor’s offices throughout Florida in 2017, quickly gaining support from the state’s medical community. Following a strong endorsement from the American Medical Marijuana Physicians Association (AMMPA), Alternate Health rapidly onboarded new physicians, clinics and patients. As of September 2018, FlorPass has over 7,500 patients registered in the system.

With innovative security and compliance features, FlorPass greatly increases the efficiency of the Florida medical cannabis industry. The system offers patients, producers and regulators a full suite of digital tools to manage and facilitate all transactions within Florida’s medical cannabis economy. As a cloud-based, blockchain platform, FlorPass is easily scalable to capture market share throughout Florida.

For more information about Alternate Health, visit www.alternatehealth.com.

About Liberty Health Sciences Inc.

Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience because of our genuine care for all cannabis users and a focus on operational excellence from seed to sale and beyond. Liberty’s stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near-and mid-term opportunities while keeping consumers' well-being at the forefront of what we do. Liberty has an extensive background in highly regulated industries and leverages its commercial greenhouse expertise to drive low-cost production. For more information, please visit: www.libertyhealthsciences.com.

About FlorPass

FlorPass is a blockchain-enabled software platform that manages the end-to-end transactions involved in providing safe access to medical cannabis to eligible patients. The system provides secure access to patients, physicians and licensed dispensaries, all linked through a seamless interface, with the ability to process medical cannabis transactions and facilitate enhanced medical treatment recommendations, focused on improving patient outcomes.

Approved by the Florida Department of Health and endorsed by the American Medical Marijuana Physicians Association, FlorPass is the state’s first online shopping portal for medical cannabis equipped with digital transaction capabilities.

About Alternate Health

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. Through its software solutions, data analytics and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.ca.

Investor Relations Contact:

Jim Griffiths, Director

1.416.607.5757 | j.griffiths@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects, anticipated lab sample increases and potential revenues, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.


ALTERNATE HEALTH SIGNS AGREEMENT WITH LIBERTY HEALTH SCIENCES TO LAUNCH FLORIDA’S FIRST ONLINE SHOPPING PORTAL FOR MEDICAL CANNABIS

SAN ANTONIO, TX. September 4, 2018 – Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF), an international corporation that provides software solutions for the medical cannabis industry, today announced that the Company has entered into a software-as-a-service agreement with Liberty Health Sciences (“Liberty”), a premiere producer and dispenser of medical cannabis in the U.S., to provide e-commerce and digital transaction services in the Florida market.

“FlorPass has received tremendous response from our physician partners in Florida and we are pleased to be working with Liberty to bring new and innovative solutions to our rapidly expanding patient population,” says Dr. Michael Murphy, Chairman and CEO of Alternate Health. “Our team has developed a truly unique system and, through the agreement with Liberty, we are positioned for excellent growth in the Florida market.”

Liberty Health Sciences and Alternate Health were granted approval by the Florida Department of Health to implement FlorPass as the state’s first online shopping portal for medical cannabis equipped with a digital transaction system. Patients will now have the ability to browse medical cannabis products, make purchases and arrange delivery through the FlorPass secure online portal. FlorPass is the patient management software of choice for many of the state’s leading cannabis clinics and physicians, representing nearly 6,000 medical cannabis patients.

“We are proud to partner with a market leader and innovator like Alternate Health to provide best in class ecommerce access to the quality, value, and industry-leading expertise of our Liberty brands and services,” said George Scorsis, CEO of Liberty Health Sciences. “Our customers will now have online access to our growing product line with easy to navigate search capabilities, including filtering by brand and price. FlorPass is the perfect solution for us to deliver on our promise of exceptional user experience without sacrificing functionality or security.”

FlorPass charges a transaction fee based on a percentage of sales through the system’s e-commerce platform. Alternate Health anticipates strong revenues based on the growing patient base and Liberty’s strong brand presence across the state.

FlorPass is a blockchain-enabled software platform that manages the end-to-end transactions involved in providing safe access to medical cannabis to eligible patients. The system is accessible by the patient, certified doctors and licensed dispensaries, linked through a seamless interface, and is used to facilitate online purchases of medical cannabis and provide enhanced medical treatment recommendations, with a focus on improving patient outcomes.

About Liberty Health Sciences Inc.

Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience because of our genuine care for all cannabis users and a focus on operational excellence from seed to sale and beyond. Liberty’s stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near-and mid-term opportunities while keeping consumers' well-being at the forefront of what we do. Liberty has an extensive background in highly regulated industries and leverages its commercial greenhouse expertise to drive low-cost production. For more information, please visit: www.libertyhealthsciences.com.

About FlorPass

FlorPass is the U.S. equivalent of Alternate Health's cornerstone CanaPass Cannabis Compliance technology. Alternate Health's CanaPass system is currently live nationwide in Canada through a partnership with National Access Cannabis (‘NAC'), Canada's largest chain of medical cannabis clinics. Alternate Health's agreement with Liberty to use FlorPass is based on a fee calculated as a percent of total transactions made in the system and has been established for an initial period of 6 months with an automatic renewal period of 1 year unless either party opts to terminate.

About Alternate Health

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. This sophisticated cross-integration of the company's enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.ca.

Investor Relations Contact:

Jim Griffiths, Director

1.416.607.5757 | j.griffiths@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects, anticipated lab sample increases and potential revenues, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.


ALTERNATE HEALTH ANNOUNCES PRIVATE PLACEMENT CLOSINGS

SAN ANTONIO, TX. August 31, 2018 – Alternate Health Corp. (“Alternate Health” or the “Company”) (CSE:AHG) (OTCQB:AHGIF), an international leader in software solutions for the medical cannabis industry, wishes to announce that it is undertaking a non-brokered private placement (the “Private Placement”) of unsecured convertible notes (the “Notes”) under prospectus exemptions available under applicable securities legislation in the aggregate principal amount of up to CAD$1,700,000 (USD$1,300,000), maturing and payable on the date that is three years from the date of issuance (the "Maturity Date"). The Note shall bear simple interest at a rate of 10% per annum. Interest is payable by the Company on a quarterly basis in arrears. The first interest payment will be September 30, 2018 (or the first business day thereafter) and subsequent interest payment dates during the term will be December 31, March 31 and June 30 (or the first business day thereafter). At the Noteholders’ option, the Notes may be converted into common shares (the “Shares”) at a price of CDN $0.59 per Share (the “Conversion Price”), subject to the policies of the Canadian Securities Exchange (the “Exchange”). Included in the convertible note placement is a US$775,000 subscription by Dr. Michael Murphy, Chairman and CEO the Company.

Private Placement of Common Shares

The Company also announces that it is undertaking a non-brokered private placement of up to 6,046,511 common shares at a price of CAD$0.43 (USD$0.33) per common share for aggregate gross proceeds of up to CAD$2,600,000 (USD$2,000,000). The Company may pay finder’s fees as permitted by applicable securities laws and the policies of the CSE.

“We are extremely pleased to have closed these private placements which will facilitate important expansion opportunities in our product distribution and CBD marketing businesses supported by our blockchain enabled payment software”, says Dr. Murphy, CEO of Alternate Health.

In addition to funding expansion opportunities in product distribution and CBD marketing, private placement proceeds will be used in Alternate Health’s CanaPass and Laboratory businesses and for general working capital purposes. The proposed issuance of Notes to a non-arms’ length party constitutes a related-party transaction under MI 61-101. Because the Company’s shares trade on the CSE, the issuance of securities is exempt from the formal valuation requirements of Section 5.4 of MI 61-101 pursuant to Subsection 5.5(b) of MI 61-101 and exempt from the minority approval requirements of Section 5.6 of MI 61-101.

Grant of Stock Options

The Company also announces the grant of 60,000 stock options to a recently appointed Company director with a term of 5 years at an exercise price of CDN $0.74 per share being the closing price the day he joined the Board.

For more information about Alternate Health, visit www.alternatehealth.com.

About Alternate Health

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company’s other verticals. This sophisticated cross-integration of the company’s enterprises has positioned Alternate Health as one of the only cannabis companies that can deliver consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health’s goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Jim Griffiths, Director

1.416.607.5757 | j.griffiths@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects, anticipated lab sample increases and potential revenues, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.


ALTERNATE HEALTH SIGNS CONTRACT EXPECTED TO SIGNIFICANTLY INCREASE LAB BUSINESS

SAN ANTONIO, TX. August 7, 2018 – Alternate Health Corp. (“Alternate Health” or the “Company”) (CSE:AHG) (OTCQB:AHGIF), an international leader in software solutions for the medical cannabis industry, announced today that the Company signed a binding contract on August 6, 2018, to provide laboratory services for a large multistate laboratory provider.

Alternate Health expects to begin testing samples in August and is targeting a ramp up to a monthly sample rate of 25,000 – 30,000 by December 2018. August is forecasted to begin with approximately 5,000 to 6,000 samples monthly with an increase of 5,000 to 6,000 additional samples per month. The assumptions on sample volumes, both to start in August and the December projections, were made after carefully reviewing the current needs and future growth projected by the referring entity.

Regional fees per sample run between US$50.00 to US$250.00, with averages falling into the US$130 to US$150 range. Costs and expenses associated with performing the tests certainly vary with volume, with Alternate Health’s historical numbers falling between US$35.00 to US$70.00 per sample.

“This is a major step forward for the Company and Alternate Health Labs,” says Dr. Michael Murphy, Chairman and CEO of Alternate Health. “This deal represents the culmination of all the hard work and dedication we have put into our laboratory strategy.”

In late 2017 through 2018, the Company completed a program of upgrades at Alternate Health Lab’s San Antonio facility. As a result, Alternate Health Labs now has the capacity to run blood, toxicology, allergy, pharmacogenetics, respiratory pathogen panels and women’s health panels.

“With this agreement, Alternate Health will benefit from the investments we have made in our laboratory business,” says Dr. Murphy. “We are excited to build a stable financial foundation to move forward with our mission to be the technology leader in the international cannabis industry.”

Company Updates

Dr. Michael Murphy will also provide an update to the last CEO Report in the next week as promised.

For more information about Alternate Health, visit www.alternatehealth.com.

About Alternate Health

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the Company’s other verticals. This sophisticated cross-integration of the company’s enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health’s goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity.

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Jim Griffiths, Director

1.416.607.5757 | j.griffiths@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects, anticipated lab sample increases and potential revenues, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.


RESIGNATION OF DIRECTOR

SAN ANTONIO, TX. August 3, 2018 – Alternate Health Corp., ( ‘Alternate Health’ or the ‘Company’ ) (CSE:AHG) (OTCQB:AHGIF), an international leader in software solutions for the medical cannabis industry, announced today that due to increasing commitments in other activities Mr. J. Bernard Rice has tendered his resignation as a director of the Company. The Company would like to thank Mr. Rice for his assistance while serving as a director and wish him well in his endeavors.

About Alternate Health

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company’s other verticals. This sophisticated crossintegration of the company’s enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health’s goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity.

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Jim Griffiths, Director

1.416.607.5757 | j.griffiths@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”. Forwardlooking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects, financing plans and spin off plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.


ALTERNATE HEALTH ANNOUNCES STRATEGIC PRIVATE PLACEMENT OF CONVERTIBLE NOTES

SAN ANTONIO, TX. June 14, 2018 – Alternate Health Corp., ( ‘Alternate Health’ or the ‘Company’ ) (CSE:AHG) (OTCQB:AHGIF), an international leader in software solutions for the medical cannabis industry, announced that on June 22, 2018 it completed a private placement (the “Offering”) of secured convertible notes (the “Notes”) having a face value of up to $1,300,000 CAD. The Notes bear interest at the rate of 12% per annum, with accrued interest payable quarterly and a maturity date of 18 months from the date of advance. The Notes are secured by the Company’s pledge of marketable securities held by it. The Company may prepay the Notes before the maturity date, subject to paying lump sum interest equal to a maximum of 12 months’ interest minus interest paid to the date of prepayment.

The holders of the Notes may convert at any time, all or a portion of the principal into common shares of the Company at a price of $0.77 per common share. Interest may be convertible, subject to the Company’s further filing requirements with the Canadian Securities Exchange.

As additional consideration for the investment in the Notes, the Company will grant 1,688,311 warrants (the “Warrants”) to the holders of the Notes. The Warrants have a three year term and each Warrant is exercisable into common shares of the Company at an exercise price equal to the conversion price under the Notes. All private placement securities will be restricted from trading for a period of four months from closing.

Dr. Michael Murphy CEO of Alternate Health commented, “ We are pleased to have attracted investors with strategic relationships in the cannabis industry who can play a significant role in raising future capital and making potential customer introductions.” Murphy also noted, “the proceeds of the private placement will be used for enhanced marketing of our CanaPass software and our Zi app payment engine as well as for general working capital purposes.”

For more information about Alternate Health, visit www.alternatehealth.com.

About Alternate Health

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company’s other verticals. This sophisticated cross-integration of the company’s enterprises has positioned Alternate Health as one of the only cannabis companies that can deliver consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health’s goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity.

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Jim Griffiths, Director

1.416.607.5757 | j.griffiths@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects, financing plans and spin off plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.


JEFF LANGENBACH JOINS ALTERNATE HEALTH’S BOARD OF DIRECTORS

SAN ANTONIO, TX. June 14, 2018 – Alternate Health Corp., ( ‘Alternate Health’ or the ‘Company’ ) (CSE:AHG) (OTCQB:AHGIF), an international leader in software solutions for the medical cannabis industry, is pleased to announce that Jeff Langenbach has been appointed to the Company’s Board of Directors.

Mr. Langenbach has over 25 years of experience in management, finance, corporate development, and mergers and acquisitions. In addition to his financial expertise, Mr. Langenbach will strengthen the Board’s international perspective, with his significant experience managing business activity in over 30 countries, spanning six continents.

“This is an exciting new addition to the Company’s Board of Directors,” says Dr. Michael Murphy, Chairman and CEO of Alternate Health. “Jeff’s experience and expertise comes at a key moment for the Company, as we ramp up our operations across all our verticals.”

Mr. Langenbach spent 12 years on Wall Street with DLJ, CS-First Boston, and Credit Suisse, raising debt and equity capital, advising on M&A transactions and helping form joint ventures. During this period, he helped raise over $10 billion, advised on numerous cross-border M&A assignments and participated in over 20 IPOs.

For the past 10 years, Mr. Langenbach has been part of the senior management team at Vanta Education (FKA Apollo Education Group). Mr. Langenbach led the formation of Apollo Global, an international subsidiary, which had worldwide operations in Australia, Brazil, Chile, South Africa, Germany, Mexico, the UK, India, and the United States, with revenues exceeding $500 million.

“As one of the earliest investors in Alternate Health, Jeff has been a committed and long-term supporter of the Company from day one,” says Dr. Murphy. “We are confident his appointment will strengthen the Board’s representation of shareholder and investor interests.”

Mr. Langenbach’s education includes a Master's Degree in Management from the Kellogg School of Management at Northwestern University and a Bachelor's Degree in Business Administration from the University of Wisconsin-Madison.

Company Updates and Insider Buying

As discussed during a recent shareholder call, Alternate Health will be releasing an update to investors within the next seven to 10 days. Dr. Murphy, Chairman and CEO, will provide insight on the Company’s operations and ongoing strategy in a letter to shareholders.

About Alternate Health

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company’s other verticals. This sophisticated cross-integration of the company’s enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health’s goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.com.

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Jim Griffiths, Director

1.416.607.5757 | j.griffiths@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forwardlooking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects, financing plans and spin off plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.


ALTERNATE HEALTH CEO UPDATES SHAREHOLDERS ON SPINOFF PLANS

SAN ANTONIO, TX. May 10, 2018 – Alternate Health Corp., ("Alternate Health") (CSE:AHG) (OTCQB:AHGIF), an international leader in software solutions for the medical cannabis industry, updated shareholders today on the Company’s spinoff plans and key milestones for the upcoming quarters.

“The Company has been very active this year adjusting our business for revenue generation and growth, including developing our potential spinoff plan for Alternate Health’s non-cannabis assets,” says Dr. Michael Murphy, Chairman and CEO of Alternate Health. “We are excited about this plan, but we want to assure our shareholders that we will only act on this plan when the right conditions are met across the business.”

Management has received Board approval to explore a spinoff plan for the Company’s noncannabis assets, it is estimated to take at least three to four months to complete this due diligence process. In the meantime, there are at least four key milestones Alternate Heath plans to meet before acting, including:

  1. Laboratory referrals back above 10,000 samples per month and growing.
  2. Our payment engine for non-cannabis transactions has at least 2 contracts with testing and implementation underway.
  3. Cannabis payment engine fully integrated to the CanaPass/StatePass system and revenue has started.
  4. Recreational cannabis sales have started with a good business plan and prospects for future growth.

Should the above criteria be met, and final decision made, the Board expects to seek shareholder approval and that all shareholders would receive their pro rata share of ownership in both companies, on a 1:1 ratio. Tax implications must also be considered prior to a final decision being taken.

Alternate Health’s focus continues to be on maintaining shareholder value, therefore:

  • Only equity dilution to be based on any capital raise associated with the Newco offering.
  • Part of any newly raised capital would be used to hire management to oversee and expand each new primary division in the company.

No decision has been made on the final division of company assets between the NewCo and Alternate Health. In particular, Alternate Health is exploring different options for the Company’s laboratory business. The Lab could move to the non-cannabis NewCo or stay in Alternate Health. Another option could see the Lab move to the NewCo and pay a long-term royalty to Alternate Health.

“We believe the proposed spinoff of the Company’s non-cannabis assets is the best plan to maximize the value and revenue potential of the Company’s assets,” says Dr. Murphy. “The Board will be busy performing our due diligence and will update shareholders in time.”

Independent Director Resigns

The Company also announces a change to Alternate Health’s Board of Directors. Kristin Taylor has tendered her resignation as an independent director to focus on her full-time career obligations. On behalf of the Board of Directors, Alternate Health’s Chairman and CEO, Dr. Michael Murphy, would like to thank Kristin Taylor for her support and service to the Company. The Company is actively looking for an independent director to fill Ms. Taylor’s seat on the Board, and will do so in the near future.

About Alternate Health

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company’s other verticals. This sophisticated crossintegration cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health’s goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.com.

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Jim Griffiths, Director

1.416.607.5757 | j.griffiths@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forwardlooking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects, financing plans and spin off plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.


ALTERNATE HEALTH ANNOUNCES PLAN TO UPLIST BLOCKCHAIN FINTECH HEALTHCARE BLOCKCHAIN ASSETS VIA CORPORATE SPINOFF

SAN ANTONIO, TX. May 1, 2018 – Alternate Health Corp., ("Alternate Health") (CSE:AHG) (OTCQB:AHGIF), an international leader in software solutions for the medical cannabis industry, announced today a proposed plan that it believes will substantially increase shareholder value through a spinoff of the Company’s blockchain payment systems, Alternate Health Labs subsidiary and other non-cannabis assets into a new corporation that will apply to be listed on a major American exchange.

"We have received an extremely high level of interest in Alternate Health’s new blockchain solutions for our laboratories and payment processing systems," says Dr. Michael Murphy, Chairman and CEO of Alternate Health. "We believe these technologies represent the future of both the Fintech and healthcare industries, with the potential to open up new business opportunities in some of the world’s most valuable markets."

Proposed Fintech / Healthcare Company

Alternate Health has taken a leadership position in blockchain financial and healthcare solutions. A key product is the company’s Zi App Blockchain Payment Gateway. Originally designed to facilitate digital payments in cannabis, this system has earned overwhelming interest as a payment solution for even larger markets, like multi-level marketing, commercial leases and equipment rentals. The new company would be free to negotiate licensing and strategic partnerships without the association of cannabis.

"As it stands, we feel these assets are undervalued in the context of the cannabis company, so we are seeking a platform to launch our technology in new markets beyond the scope of Alternate Health’s cannabis focus," says Dr. Murphy. "An uplisting would give us the shareholder value and market liquidity to take on these exciting market opportunities and deliver shareholders an additional opportunity for a strong return on their investment."

Alternate Health Labs would also be included in the new company, since it forms another revenue-generating, non-cannabis asset. The new company would be able to negotiate greater referral contracts for the business, while applying its expertise in blockchain development to software and management systems across the healthcare industry.

Alternate Health’s Future in Cannabis

Spinning off the company’s blockchain payment and laboratory assets is expected to have a dramatic impact on Alternate Health’s cannabis businesses. This process will free up the company to immediately focus on generating revenue from of our CBD products, with Alternate Health already pursuing production and distribution deals in California, Canada and Mexico. A cannabis-focused Alternate Health will also be free provide software services to recreational markets across the United States and Canada.

"We expect this change will position Alternate Health’s cannabis assets for explosive growth as we are free to expand our operations into production and distribution," says Dr. Murphy. "This restructuring would allow us fully monetize all our cannabis assets, including software, CBD products, patented delivery systems and education.”

Proposal Specifics

While still subject to board and regulatory approval, including shareholder approval if required, the plan would see all cannabis-specific assets remain in Alternate Health. This includes the subsidiaries of Alternate Health Inc., Alternate Medical Media, LLC, and Alternate Health Life Sciences, LLC. Alternate Health USA Inc. and Alternate Health Labs Inc.* would be spun off to form a new public company, which would apply to be listed on an American exchange.

Alternate Health is in the process of preparing complete and representative prospectuses for the proposed spin-off. Separating the companies will materially affect the company’s financial projections for 2018 and, in the near future, issue revised projections for the new companies. For the first time, the company will report projections for individual business lines as opposed to the company as a whole. Alternate Health’s goal is to make these projections available to the public in six to eight weeks.

*Note: The spinoff of the Company’s laboratory business would affect Alternate Health’s previously stated revenue projections, and once the details of the spin off plan are confirmed, the Company will update on how the plan is expected to impact previously disclosed revenue projections.

General terms of the proposed plan:

  • NewCo will apply to be listed on an American exchange.
  • Management will seriously consider legal and accounting advice to create an ownership structure that best maintains shareholder valuations, while maximizing tax efficiencies.
  • As a preliminary plan, no timetable has been set and final agreements are still subject to board, shareholder and regulatory approval and considerations of tax, corporate and securities matters in the United States and Canada.

About Alternate Health

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company’s other verticals. This sophisticated crossintegration cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health’s goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.com.

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Jim Griffiths, Director

1.416.607.5757 | j.griffiths@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forwardlooking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations, business prospects, financing plans and spin off plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.


ALTERNATE HEALTH LAUNCHES FIRST COMPLETE ETHEREUM BLOCKCHAIN EMR / EHR

SAN ANTONIO, TX. April 19, 2018 – Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF), an international leader in software solutions for the medical cannabis industry, today announced the transformation of the CanaPass Patient Management system to a complete Ethereum-based blockchain Electronic Medical Records (‘EMR') / Electronic Health Records (‘EHR') system.

"Alternate Health's blockchain EMR/EHR is the first of its kind and completes our comprehensive integration of blockchain technology into all aspects of our software systems," says Dr. Michael Murphy, Chairman and CEO of Alternate Health. "Along with the deployment of our Zi App Blockchain Mobile Payment System and our CanaPass blockchain transaction ledger, Alternate Health is leading the paradigm shift in emerging healthcare data and medical cannabis technology."

How the CanaPass Blockchain EMR works:

Based on Ethereum's platform, CanaPass' HIPAA and PIPEDA-compliant system records key medical data in blocks on a distributed ledger. Each patient's CanaPass account includes its own private cryptographic key that is used to identify and decrypt the associated private information from the distributed ledger. This is similar to the way a blockchain wallet works, but instead of keeping track of tokens or digital assets, it is used to track and store data such as the patient's lab results, medical reports, etc.

Key Advantages of Alternate Health's Blockchain EMR/EHR:

  • Reliability: The use of decentralized, cloud-based storage ensures maximum reliability and prevents data loss through regular automated backups of all data.
  • Security: All sensitive patient data storage exceeds HIPAA and PIPEDA requirements; Since only the hash value of sensitive data is stored on the blockchain, data can only be decrypted with the private key of that account.
  • Transparency: The use of a distributed ledger ensures data is tamper-proof, preventing cyber-attacks on the system itself since previous transaction data cannot be changed or overwritten.

Alternate Health developed the CanaPass Blockchain EMR/EHR in conjunction with Support Your Buds LLC (‘SYB'), a leader in custom Blockchain and Smart Contract solutions. Previously, Alternate Health and SYB have collaborated in the development of the Zi App Blockchain Payment system.

For more information on the CanaPass Blockchain EMR/EHR system, download the technical description at https://supportyourbuds.com/blockchain-EMR-Tech.pdf. Technical information for Zi App can also be downloaded from https://supportyourbuds.com/Zi-App-Tech.pdf.

Additional Expansion in the U.S. and Canada

Alternate Health also indicated that the Company has begun expanding its presence in the Florida medical cannabis market with the rollout of FlorPass, its Florida-focused adaptation of CanaPass, at all Florida Compassionate Care Clinics of America (‘CCCofA') locations. CCCofA operates three medical clinics in Florida and is poised for significant growth with an additional four locations slated to open in 2018.

"I am impressed with the ease of use and reporting ability, and the willingness of the Alternate Health staff to quickly and easily modify their setup and templates to suit our needs as a medical marijuana evaluation clinic," says Debbie Mendez-Vigo, a managing partner at CCCofA. "Their support has been outstanding! I look forward to working with Alternate Health on their FlorPass system to expand our research capabilities and future development as well as serve the needs of the cannabis community."

About Alternate Health

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. This sophisticated cross-integration of the company's enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.com.

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Jim Griffiths, Director

1.416.607.5757 | j.griffiths@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.


ALTERNATE HEALTH LAUNCHES 'ZI APP' – THE LATEST INNOVATION IN FIXED-EXCHANGE BLOCKCHAIN MERCHANT GATEWAYS

SAN ANTONIO, TX. April 17, 2018– Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF), ), an international leader in software solutions for the medical cannabis industry, today announced the launch of Zi App, an innovative mobile wallet payment processing solution built on proprietary blockchain and smart contract technology.

"Zi App is a game changer in the FinTech industry," says Dr. Michael Murphy, Chairman and CEO of Alternate Health. "By integrating Alternate Health's mobile payment engine and digital e-wallet with a state-of-the-art blockchain platform, we have created a groundbreaking alternative to high-priced merchant transaction processing—perfectly suited to any and all high-risk industries, including legal cannabis."

Benefits of the Zi App Blockchain Payment System:

  • Low Cost Transactions: Zi App uses fixed-price, utility tokens to facilitate all transactions and offer merchant payment processing services at a much lower cost than traditional banks or payment service providers.
  • Consumer Protection Compliance: Unlike cryptocurrencies, Zi App allows for chargebacks and reversals, which is a key feature for high-risk industries like online retailers, who are required to offer these services to comply with consumer protections laws
  • Dispute Protection: Zi App tracks all transaction data on a blockchain ledger, creating an immutable and secure record of transactions, with smart contracts that automatically initiate transactions when the terms of a digital agreement are met.
  • Market Versatility: In addition to being an ideal fit for legal cannabis transactions, Zi App is an optimal solution for any high-risk industry, ranging from payday loans and network marketing to dating services and online gaming.

How Zi App Works:

The Zi App platform delivers payment processing services through a comprehensive, direct-to-bank merchant transaction system. For every transaction, a receipt is generated on the platform's blockchain distributed ledger, ensuring full security and transparency.

Alternate Health has developed Zi App as a 50/50 partnership with leading blockchain developer Support Your Buds LLC ("SYB"). Based on Alternate Health's payment engine and Support Your Buds LLC's proprietary smart contract and blockchain ledger technology, the Zi App system is powered by the Zi Utility Token. Unlike cryptocurrencies, Zi's have a fixed 1:1 value to U.S. dollars, protecting the system from the instability and speculation of digital assets like Bitcoin.

"We expect the legal cannabis companies along with other high-risk industries, to embrace Zi App as their preferred payment processing solution," says Jim Griffiths, Company Director and Sr. VP Finance, "This is revolutionary, disruptive technology and we have already established merchant partners who are eager to begin pilot testing a system that we believe will reinvent the rules of modern merchandising."

SYB is 75% controlled by a shareholder of the Company that owns directly and indirectly, approximately 12% of Alternate Health's outstanding shares. Additionally, Dr. Murphy, Chairman and CEO of Alternate Health is a 20% shareholder of SYB. The specific terms of the 50/50 partnership arrangement between Alternate Health and SYB are not yet finalized, but Dr. Murphy has disclosed his SYB shareholding to the Company and abstained from discussions and negotiations between the Company and SYB in relation to the Zi App

About Alternate Health Corp.

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. This sophisticated cross-integration of the company's enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.ca.

About Support Your Buds LLC

Support Your Buds LLC is a leader in developing blockchain software solutions customized to the business needs of its clients. With an initial industry focus on finance and healthcare, Support Your Buds LLC uses its proprietary blockchain and smart contract platforms to build dynamic solutions that drive efficiencies in any market.

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Jim Griffiths, Director

1.416.607.5757 | j.griffiths@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.


ALTERNATE HEALTH'S STATEPASS EMR AND CANNABIS COMPLIANCE BLOCKCHAIN TAKES ON NEW YORK MARKET, BEGINS PHYSICIAN ONBOARDING

SAN ANTONIO, TX. April 5, 2018– Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF), an international software solutions leader in the medical cannabis industry, today announced that the Company is expanding its StatePass medical cannabis Electronic Medical Records (EMR) blockchain system in New York, commencing physician onboarding and initial service testing.

"We have already identified several cannabis physicians to begin service testing StatePass in New York, where they will use the EMR for their current cannabis patients and provide feedback so our programming team can optimize the system for statewide use," says Dr. Michael Murphy, Chairman and CEO of Alternate Health. "Based on the positive feedback we have already received from physicians, we are confident that our presence in the New York market will expand rapidly."

StatePass is the only EMR and blockchain-enabled software solution specifically designed for the medical cannabis industry. A complete practice management tool, StatePass ensures strict regulatory compliance with a focus on improving patient outcomes. StatePass is also an ideal software solution for highly regulated markets, like New York, with an easy-to-use interface that allows physicians to personalize their patients' treatment options with built-in, automated compliance reporting.

The arrival of StatePass in the New York market follows the success of the system's original version CanaPass and the Florida-specific adaptation – FlorPass. Boosted by the American Medical Marijuana Physicians Association's recent endorsement of FlorPass, the system is rapidly expanding across Florida, with AMMPA President Dr. Orlando Florete declaring: "We believe that CanaPass will help empower these physicians with the tools required to effectively and compliantly help those patients in need."

"Our New York team is working closely with physicians to familiarize them with the StatePass system and demonstrate how it can be a tremendous asset in enhancing their medical cannabis practices," says Jay Briggs, Vice President of Operations for Alternate Health. "We are very excited to continue developing our network of physicians and industry experts as we deliver a best-in-class EMR solution."

About StatePass

StatePass is the U.S. equivalent of Alternate Health's cornerstone CanaPass Cannabis Compliance technology. Alternate Health's CanaPass system is currently live nationwide in Canada through a partnership with National Access Cannabis (‘NAC'), Canada's largest chain of medical cannabis clinics. Listed on the TSX Venture Exchange, NAC is currently expanding into recreational markets. CanaPass will launch its recreational adaptation in all future NAC recreational locations.

About Alternate Health Corp.

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. This sophisticated cross-integration of the company's enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.ca.

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.


ALTERNATE HEALTH SIGNS AGREEMENT WITH MEDMEN TO LAUNCH STATEPASS BETA IN NEW YORK DISPENSARIES

SAN ANTONIO, TX. March 7, 2018 – Alternate Health Corp. ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF), an international, vertically-integrated company providing software solutions and laboratory services to the medical cannabis industry, today announced the release of revised revenue projections for 2018 demonstrating a positive outlook for the next 12 months.

"Alternate Health experienced two main delays at the end of 2017, which prevented the company from reaching our anticipated revenue targets," says Dr. Michael Murphy, Chairman and CEO of Alternate Health. "However, we have had a bright start to 2018 and we expect we will reach a $73 million revenue target by the end of this fiscal year with only a one quarter delay."

REVISED AHG 12 MONTH PROJECTIONS: Q1 2018 – Q4 2018*

Total Net Revenue: $73,083,000

Total EBITDA: $33,410,000

Date Net Revenue EBITDA
Q1 2018 $3,857,000 $1,671,000
Q2 2018 $14,491,00 $5,512,000
Q3 2018 $25,528,000 $11,026,000
Q4 2018 $29,207,000 $15,201,000


EBITDA represents Earnings Before Interest, Taxes, Depreciation and Amortization.

After the comments made by U.S. Attorney General Jeff Sessions prior to recreational legalization in California, beta testing and contract negotiations for Alternate Health's software business were delayed for a month as stakeholders adjusted to the new market conditions. Following this delay, Alternate Health is moving ahead with its software rollout, recently beginning beta-testing with MedMen dispensaries across New York.

The Company's laboratory business also experienced a significant delay in transitioning to a full-service clinical lab, receiving its Medicare license two months later than expected on Dec. 1, 2017. With the laboratory transition complete, sample processing has resumed with consistently strong volumes and a wider referral base.

"As a result of the delays, I believe Alternate Health's current stock price in no way reflects the underlying value of the company," says Dr. Murphy. "I am showing my confidence, personally buying 367,300 shares on the open market over the past several months, including 250,000 shares in the last three days."

*The above projections assume that Alternate Heath Labs, Inc. continues to grow its rep base which refers physician patient blood and toxicology samples to our lab for testing. It also assumes maintaining and developing partner/consulting arrangements related to hospital referrals. In addition, the projections assume the successful growth of CanaPass and its FlorPass and StatePass variants across Canada and the United States. NAC currently has over 10,000 patients registered its clinics and that number is expected to grow as additional clinics are added and as they pursue retail expansion in recreational markets. Also, based on work with the AMMPA and state approved US licensed producers, these projections assume initial software installation by users in these states providing capacity for transaction fees from an initial US customer base estimated to be 100,000 with significant growth potential in those and other states. Failing these assumptions, including a stagnant or shrinking rep base, lack of further hospital relationships, cessation of the relationships with NAC, MedMen and the AMMPA these projections could be materially wrong. Associated risks include changing government regulations related to US federal marijuana laws and for clinical laboratories and Medicare reimbursement rates. Competition factors could also impact these projections.

About Alternate Health Corp.

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. This sophisticated cross-integration of the company's enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit 

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements. EBITDA as reported in this news release is a non-IFRS measure and therefore may not be comparable or compatible to similar measures presented by other companies. Please refer to the Company's Management Discussion & Analysis for additional information about the Company's .


ALTERNATE HEALTH SIGNS AGREEMENT WITH MEDMEN TO LAUNCH STATEPASS BETA IN NEW YORK DISPENSARIES

SAN ANTONIO, TX. March 1, 2018– Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF), an international corporation that provides software solutions for the medical cannabis industry, today announced that the Company has entered into a software-as-a-service agreement with MedMen, one of the largest cannabis companies in the U.S., to provide e-commerce and digital payment services. Alternate Health's StatePass system will begin beta testing with MedMen in their New York dispensaries.

"We are very pleased to be working with MedMen as Alternate Health expands into another key state in the U.S. market," said Dr. Michael Murphy, Chairman and CEO of Alternate Health. "The implementation of CanaPass in Canada as well as beta testing in Florida have seen overwhelmingly positive response from our customers and we look forward to serving the medical cannabis community in New York with our state-of-the-art system."

The StatePass system is a cloud-based software platform that manages the end-to-end transactions involved in providing safe access to medical cannabis to eligible patients. The database is accessible by the patient, certified doctors and licensed dispensaries, linked through a seamless interface, and is used to monitor the individual patient and provide enhanced treatment recommendations, with a focus on improving patient outcomes.

"Alternate Health's agreement with MedMen is perfectly aligned with our goal of bringing best-in-class software solutions to the medical cannabis market," said Jay Briggs, Vice President of Operations of Alternate Health. "This is an exciting opportunity to work side-by-side with another leading company in the cannabis industry and open up new revenue streams in New York's tremendously promising market."

About MedMen

MedMen is headquartered in Culver City, California and operates dispensaries and production facilities in three states, including their soon to open flagship location on Fifth Avenue in Manhattan, NY. MedMen has been recognized as a leader in the cannabis industry and recently announced their intention to go public, with a listing on the Canadian Securities Exchange planned for the second quarter of 2018.

About StatePass

StatePass is the U.S. equivalent of Alternate Health's cornerstone CanaPass Cannabis Compliance technology. Alternate Health's CanaPass system is currently live nationwide in Canada through a partnership with National Access Cannabis (‘NAC'), Canada's largest chain of medical cannabis clinics. Listed on the TSX Venture Exchange, NAC is currently expanding into recreational markets. CanaPass will launch its recreational adaptation in all future NAC recreational locations. Alternate Health's agreement with MedMen to use StatePass is based on a fee calculated as a percent of total transactions made in the system and has been established for an initial period of 6 months with an automatic renewal period of 1 year unless either party opts to terminate.

About Alternate Health Corp.

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. This sophisticated cross-integration of the company's enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc.. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.ca.

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.


ALTERNATE HEALTH STRENGTHENS FINANCIAL AND PRODUCT DEVELOPMENT TEAM, APPOINTS OFFICERS AND ISSUES SECURITIES

TORONTO, February 1, 2018 – Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTC:AHGIF), an international, vertically-integrated medical cannabis company, is pleased to announce the appointment of Christopher Boling to the position of Chief Financial Officer, the appointment of Jim Griffiths to the position of Senior Vice President of Finance, the appointment of Michael Klipper to the role of Chief of Research and Product Development, and the issuances of common shares and incentive stock options.

"Following Alternate Health's excellent 2017, it is with excitement that we prepare for even greater success in 2018 with a strengthened financial and product development team," says Dr. Michael Murphy, CEO of Alternate Health. "These new appointments set the stage for rapid growth across all our verticals."

Financial Officers

Christopher Boling was appointed as the Company's Chief Financial Officer effective January 25, 2018. He takes over from Jim Griffiths who has been appointed Senior Vice President Finance effective January 25, 2018. Mr. Griffiths continues to serve as a director of the Company. On the announcement, Griffiths commented: "Chris Boling's experience makes him ideally suited to be our CFO and I look forward to supporting him as I shift my focus to corporate finance and investor relations."

Chief of Research and Product Development

The Company is pleased to announce the appointment of Mr. Michael Klipper as Chief of Research and Product Development. Mr. Klipper is currently a director of the Company. A formulary chemist, entrepreneur, author, and fundraiser, Mr. Klipper is the Co-Founder of Cannabinoid Science International Corp. (‘CSI') and a respected member of the International Cannabinoid Research Society (‘ICRS'). Mr. Klipper is a Graduate of Farleigh Dickenson University.

CSI was established to develop precision made Cannabinoid based formulary compounds that can be manufactured world-wide and made available to individuals in need of healing. By collaborating with leading researchers in Biochemistry, Physics, Computer Science (systems biology), and Healthcare Services; CSI is committed to developing scientifically proven treatments, educating regulatory agencies, healthcare professionals, and patients, improving quality of life and health outcomes, while championing a paradigm shift in society.

Terms of Agreement with Cannabinoid Science International Corp.

Cannabinoid Science International Corp. (‘CSI'), a company owned and controlled by Mr. Michael Klipper, will direct and oversee the research and product development for Alternate Health and its subsidiaries. CSI will direct the design and development of new CBD products, improve existing products and identify and develop research studies and protocol design for clinical research studies. Working with the Company's CEO, CSI will provide leadership and develop objectives for the Research and Development at Alternate Health.

  • The CSI agreement includes a payment of 250,000 common shares of the Company at a deemed price of $2.20 CAD per share, earned over a period of six consecutive quarters commencing in Q1 2018 and ending in Q2 2019.
  • CSI will receive the first 41,667 common shares for Q1 2018, with the balance of the 208,333 shares vested as to 41,667 shares per quarter for the next four fiscal quarters, and 41,665 shares for Q2 2019.
  • The common shares shall be deliverable by the Company to CSI within thirty (30) days of the end of each quarter. The share issuance will be subject to the required four months hold period legend, pursuant to the Policies of the regulatory authorities.
  • Pursuant to the terms of the agreement, the Company has granted 300,000 incentive stock options to CSI, for the right to purchase up to an aggregate of 300,000 common shares of the Company, exercisable at the price of CAD$2.20 per share for five years.
  • 50,000 options vest in Q1 2018, with the balance of the 250,000 options vested as to 50,000 options per quarter for the next five fiscal quarters.

The stock options granted will be in accordance with the Company's Stock Option Plan and will have the required four months hold period legend, pursuant to the Policies of the CSE and regulatory authorities.

About Alternate Health Corp.

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. This sophisticated cross-integration of the company's enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals, AXIM Biotechnologies Inc., Canopy Growth Corporation, and Aphria Inc. Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.ca.

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.


CANAPASS BLOCKCHAIN SYSTEM TO EXPAND INTO RECREATIONAL CANNABIS RETAIL OUTLETS IN CANADA

SAN ANTONIO, TX. January 18, 2018 – Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF), an international corporation that provides software solutions for the medical cannabis industry, today announced that its CanaPass Blockchain Reporting System will launch in the Canadian recreational cannabis market, powering five potential National Access Cannabis (NAC) locations in Manitoba subject to the federal government passing legalized recreational marijuana legislation in 2018.

"We are excited to announce our move into Canada's recreational cannabis market, building on our partnership with National Access Cannabis," says Dr. Murphy. "Our CanaPass Blockchain system is already Canada's most advanced medical cannabis regulatory solution and we expect our recreational adaption to be an industry-changing technology as the Canadian government prepares legal cannabis legislation in the summer of 2018."

Alternate Health launched the CanaPass pilot stage in July 2017 at NAC's Halifax clinic. During the second phase of rollout in 2017, the CanaPass system launched in every additional NAC location in seven Canadian provinces. Alternate Health and NAC previously signed a Software-as-a-Service agreement whereby the Company's CanaPass blockchain software is currently powering all NAC clinics and doctor's offices.

"The CanaPass system is a game-changer in the Canadian cannabis industry," says Dr. Michael Murphy, CEO of Alternate Health. "No cannabis point-of-sale system can match its comprehensive data collection and reporting features, connecting all transactions in a blockchain ledger between customers, licensed producers, dispensaries, governments and medical professionals."

The CanaPass system is a cloud-based software platform that manages the end-to-end transactions involved with providing safe access to medical cannabis to eligible patients. The database is accessible by the patient, certified doctors and licensed producers only, and is used to monitor the individual patient and provide enhanced treatment recommendations, with a focus on improving patient outcomes.

"Regulatory compliance, data security and transparency have never been so important as cannabis legalization moves forward in Canada," adds Dr. Murphy. "Alternate Health offers the only software system that provides provincial governments and federal authorities the detailed transaction ledger and tax reporting they need, backed by our patented blockchain technology."

About Alternate Health Corp.

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. This sophisticated cross-integration of the company's enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals (OTCMKTS:GWPRF), AXIM Biotechnologies Inc. (OTCMKTS:AXIM), Canopy Growth Corporation (TSE:WEED), and Aphria Inc. (TSE:APH). Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.ca.

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.


ALTERNATE HEALTH BEGINS BETA TESTING OF FLORPASS PATIENT MANAGEMENT SOFTWARE SYSTEM IN KEY MARKET

SAN ANTONIO, TX. December 18, 2017 – Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF)), an international, vertically-integrated medical cannabis company, today announced that the Company's FlorPass patient management system is set to roll out across the state with the beta testing phase currently underway in eight locations, complete with blockchain reporting.

"Alternate Health is working daily with doctors, patients and regulators to offer the most comprehensive software system in the medical cannabis industry," says Jade Green, V.P. of Sales and Marketing at Alternate Health, who is in Florida this week training multiple physicians on the EMR software. "We are currently onboarding eight medical facilities and their patients to the FlorPass system, and we expect to have a total of 20 clinics and physician offices utilizing the software by the end of our beta test on January 15, 2018."

Alternate Health officially launched FlorPass at the American Medical Marijuana Physicians Association (‘AMMPA') Annual Conference in October 2017. The FlorPass EMR received a national endorsement from AMMPA, leading to strong support from doctors across the United States and a current waiting list of over 100 physicians.

After beta-testing is complete in January, Alternate Health expects to roll out the FlorPass software to the remaining doctors on the Florida physicians waiting list. The Company is also actively working on securing beta agreements with Medical Marijuana Treatment Centers (MMTCs), which are the licensed cultivators and dispensary operators in the state of Florida.

"FlorPass continues to gain momentum across the state, and Alternate Health is actively building a blockchain-powered network of key industry players through our technology assets," says Dr. Michael Murphy, CEO of Alternate Health. "As the Florida market becomes fully monetized, we expect this network to capture consistent and substantial revenues for our software business."

As the equivalent to Alternate Health's cornerstone CanaPass technology, FlorPass functions as a cannabis-specific electronic medical record (‘EMR') system and an e-commerce platform for qualified medical cannabis patients. Alternate's patient management software will link the physician, patient and licensed cannabis provider in a secure, closed-loop network to regulate, track and monitor medical cannabis purchases and outcomes in multiple legal markets.

Alternate Health's CanaPass system and blockchain ledger is currently live nationwide in Canada through a partnership with National Access Cannabis (‘NAC'), Canada's largest chain of medical cannabis clinics. Listed on the TSX Venture Exchange (TSXV:NAC), NAC is currently expanding into recreational markets. Alternate Health plans on launching an adaptation of CanaPass for recreational markets to be deployed in all NAC recreational locations.

About Alternate Health Corp.

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. This sophisticated cross-integration of the company's enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals (OTCMKTS:GWPRF), AXIM Biotechnologies Inc. (OTCMKTS:AXIM), Canopy Growth Corporation (TSE:WEED), and Aphria Inc. (TSE:APH). Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.ca.

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.


ALTERNATE HEALTH TO PROVIDE INVESTOR UPDATE AND LIVE Q&A ON DECEMBER 7TH VIA VIRTUALINVESTORCONFERENCES.COM

SAN ANTONIO, TX. December 6, 2017 – Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTCQB:AHGIF), an international, vertically-integrated medical cannabis company, today announced that the Company's CEO, Dr. Michael Murphy, will be webcasting live and answering questions from investors on Dec. 7, 2017.

DATE: Thursday, Dec 7, 2017

TIME: 1:00 p.m. EST

LINK: https://tinyurl.com/127prepr


This will be a live, interactive online event where investors are invited to ask Dr. Murphy questions in real-time – both in the presentation hall and the association's "virtual trade booth." If attendees are unable to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register and run the online system check to save time and receive event updates.

Learn more about the event at www.VirtualInvestorConferences.com


Recent Company Highlights:

  • Receipt of Medicare license approval for Alternate Health Labs
  • Installation of CanaPass software platform is progressing well and should be completed by year-end in National Access Cannabis' 11 Canadian clinics serving 12,000 clients.
  • CanaPass Florida-specific adaption FlorPass has launched in Florida clinics making inroads into other states with additional adaptations.
  • Negotiated the acquisition of a Blockchain-Enabled Mobile Payment software application completed in November, adding mobile payment solutions and point of sale capabilities.
  • Alternate Health Lab conversion to a full clinical lab is expected to continue generating long-term stable revenues.


About Alternate Health Corp.

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals (OTCMKTS:GWPRF), AXIM Biotechnologies Inc. (OTCMKTS:AXIM), Canopy Growth Corporation (TSE:WEED), and Aphria Inc. (TSE:APH). Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

About VirtualInvestorConferences.com

Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.


Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca


VirtualInvestorConferences.com Contact:

John Viglotti

VP, Investor Relations Products and Services

Cision / PR Newswire / MultiVu

Phone 201 360 6767 | Mobile 212 729 8350

john.viglotti@prnewswire.com


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH CORP. REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND MEDICARE LICENSE APPROVAL

SAN ANTONIO, TX. December 1, 2017 – Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTC:AHGIF), an international medical cannabis company that uses best-in-class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices, today announced its results for the third quarter ended September 30, 2017. All dollar references are in Canadian dollars unless otherwise noted.

Third Quarter 2017 Financial Highlights

  • Q3 Revenue of $1.7 million was down compared to $3.9 million in Q1 and $7.2 million in Q2, but was up substantially compared to $55K in Q3 of 2016.
  • Adjusted EBITDA of ($1.5) million in Q3 compared to $25K in Q2 2017 and ($166)K in Q3, 2016.
  • Net loss of $2.4 million compared to a net loss of $3.6 million in Q2 of 2017 and $211K in Q3, 2016.
  • Working capital of $6 million in Q3 2017 compared to $7.5 million in Q2 of 2017 and $0.5 million in Q3 2016.

As previously announced, Q3 was a planned transition quarter with an expected dip in revenues as the Company's wholly owned subsidiary, Alternate Health Labs Inc. converted its San Antonio laboratory from a Reference Lab to a Clinical Lab. This transition resulted in a temporary decrease in revenues that totaled $1.7 million in Q3 compared to $7.5 million in Q2. With the transition now successfully completed, the Company expects its laboratory revenues will be back on course in December.

There were no major capital expenditures or investments in the 3rd quarter and cash was used principally to fund operations. With the Lab conversion completed, the Company expects its consolidated operations to be cash flow positive in Q1 2018. The third quarter loss of $2.4 million includes an $800,000 non-cash charge relating to equity awards computed using fair market valuation modelling as required under accounting guidance.

Note – Alternate Health Corp ("the Company") was formed in January 2017 from a reverse take-over of a privately held operating company, Alternate Health Inc. ("AHI"). Per the accounting guidance, the Company's current year quarterly operating statements are compared to the same prior year periods of AHI. Similarly, the Company's balance sheets for the current year quarter end periods are compared to the same prior year periods for AHI.


Management Commentary

"While the anticipated decrease in revenue for the 3rd quarter is disappointing, it was projected in July because of the planned temporary closing and restructuring of our San Antonio Laboratory. We are delighted to have received approval of our Medicare license and to now be able to function as a full Clinical lab. This will prove over time to be but a small pause in the direction of this Company. Importantly, I remain confident of achieving the 12-month projections released last month." said Dr. Murphy, the Company's Chairman and CEO.

Third Quarter 2017 Operational Highlights

  • Installation of our CanaPass software platform in National Access Cannabis' 11 Canadian clinics serving 12,000 clients progressed well, and should be substantially completed by year end.
  • Installed CanaPass in Florida clinics and made meaningful inroads into other states.
  • Negotiated the acquisition of our Blockchain Mobile Payment software application completed in November. Its addition to our software platform provides a much-needed payment solution and point of sale technology to the Cannabis industry with full transparency for government transaction tracking and reporting. Alternate's platform can accept crypto currencies in its electronic wallet.
  • AHL's conversion to a full clinical lab that is expected to provide long term stable income.

STOCK OPTIONS

The Company also wishes to announce that it has granted incentive stock options to certain, officers of the Company for the right to purchase up to an aggregate of 120,000 common shares of the Company, exercisable at the price of CAD$2.00 per share for five years. The stock options granted will be in accordance with the Company's Stock Option Plan and will have the required four months hold period legend, pursuant to the Policies of the CSE and regulatory authorities.


About Alternate Health Corp.

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals (OTCMKTS:GWPRF), AXIM Biotechnologies Inc. (OTCMKTS:AXIM), Canopy Growth Corporation (TSE:WEED), and Aphria Inc. (TSE:APH). Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH ACQUIRES CANNABIS BLOCKCHAIN POINT-OF-SALE AND PAYMENT SOFTWARE SOLUTION

TORONTO, November 15, 2017 – Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTC:AHGIF), an international, vertically-integrated medical cannabis company, today announced the acquisition a new Mobile Payment Processing Application, acting as turnkey payment solution and point-of-sale technology with comprehensive Blockchain reporting.

"This acquisition is the final piece needed to fully integrate Alternate Health's cannabis-specific Electronic Medical Records (EMR) and Transaction Management software with Blockchain technology," says Dr. Michael Murphy, CEO of Alternate Health. "Our complete software suite will ensure full regulatory compliance, empowering governments with detailed financial, tax and transaction reporting and uniquely addressing the demands of the legal cannabis industry."

The regulated cannabis industry is projected to reach $30 billion USD in the United States by 2021 and up to $22.6 billion CAD in Canada according to respective reports in Forbes and Maclean's magazines1. With such rapid growth, there are numerous opportunities for technologies that ensure safety, security and transparency. Alternate Health expects to capture of a meaningful percentage of this market by offering governments the tools to track end-to-end transactions in regulated cannabis markets.

"Alternate Health's software creates a fixed engine to empower local, state and national governments to monitor end-to-end transactions and collect the exact and appropriate remuneration," says Dr. Murphy. "The new payment solutions and point-of-sale technology bolsters Alternate Health's intellectual property assets and opens up greater revenue generating capabilities for the Company's patented EMR and transaction management software."

The Mobile Payment Processing Application creates a complete end-to-end software suite for regulated cannabis businesses, based on Alternate Health's CanaPass and FlorPass software. The software will be available in not only medical cannabis markets, but also recreational cannabis legalized markets, including jurisdictions with state-level legalization, such as Washington and Colorado, and when legalized, countries with national-level legalization, such as is anticipated in Canada by July 2018.


Terms of Agreement with Trident Payments, LLC

Under the terms of the agreement, Trident Payments will assign all intellectual property rights to the Mobile Payment Processing Application to Alternate Health, including source code, algorithms, databases, software, etc. The Mobile Payment Processing Application is a fully functioning mobile application available for download on both the IOS and Android platforms and will be used to accept payments made by its customers for cannabis-related products and services. The Mobile Payment Processing Application includes a cascading feature that will facilitate the processing of credit card transactions so that if a transaction should fail it is rerouted over and over until it has been sent to all the banks available for use.

Trident Payments will receive a total of 300,000 common shares at a deemed price of $2.45 CAD per share. Upon execution of the agreement, Trident will receive the first 100,000 shares, with the balance of the 200,000 shares vested as to 50,000 shares on the first trading day of each of the next four fiscal quarters in 2018. Trident Solutions, LLC, an affiliate of Trident Payments, will also receive 24,000 common shares under a Marketing and Management agreement to integrate the technology into CanaPass and continue to make updates and improvements as necessary.

This agreement includes an aggregate $34,000 USD independent contractor fee paid monthly and automatically renewable for12 months. Alternate Health has also agreed to pay Trident Solutions, on a quarterly basis, a percentage of the net income received by Alternate Health in connection with certain payment processing transactions. All common shares will be issued in accordance with the Policies of the CSE and regulatory authorities, and be subject to a 4 month hold period under applicable Canadian securities laws.


Consulting Agreements – Issuance of Common Shares and Warrants

The Company also announces that it has entered into two agreements (the ‘Agreements') with certain consultants of the Company for providing fundraising and market awareness services. Pursuant to the terms of the Agreements, for past services rendered, the Company will grant 50,000 warrants to purchase the Company's shares at a price of CAD$2.45 per common share for a period of twenty-four (24) months from the date of issuance. The effective date of the grant is November 9, 2017. The Company will also issue 5,000 common shares at a deemed price of CAD$2.45, for past services rendered. In addition, the Company entered an agreement for multiple technology/consulting services in return for the issue of 185,000 common shares at a deemed price of CAD$ 2.45. The shares vest as to 46,250 on the first trading day of the next four fiscal quarters in 2018. The common shares and warrants granted will be in accordance with the Policies of the CSE and regulatory authorities, and be subject to a 4-month hold period under applicable Canadian securities laws.


About Alternate Health Corp.

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. This sophisticated cross-integration of the company's enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant.

Through its software solutions, data analytics, and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals (OTCMKTS:GWPRF), AXIM Biotechnologies Inc. (OTCMKTS:AXIM), Canopy Growth Corporation (TSE:WEED), and Aphria Inc. (TSE:APH). Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:

Nancy Goertzen, CPIR

1.604.512.7122 | n.goertzen@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.


1Source: Forbes.com, "The marijuana industry is getting supersized" May 8, 2017; Macleans.ca, "How big is Canada's marijuana market, really?" June 30, 2017.



ALTERNATE HEALTH LAUNCHES NEW ALTERNATEHEALTH.COM DOMAIN, PREPARES FOR FURTHER U.S. EXPANSION WITH APPEARANCE AT ETHEREUM'S DEVCON3 CONFERENCE

TORONTO, November 1, 2017 – Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTC:AHGIF), an international, vertically-integrated medical cannabis company, today announced a renewed focus on the U.S. market with the launch of the new alternatehealth.com domain while confirming attendance at Devcon3, hosted by Ethereum, a Blockchain protocol whose value skyrocketed from $72 million to $28 billion in just 2017.

"Alternate Health is growing in momentum across all of our verticals, boosting our visibility in the American medical cannabis market," says Dr. Michael Murphy, CEO of Alternate Health. "With the launch of our FlorPass software system and developments in adding Blockchain technology, Alternate Health is well prepared for this surge in interest in the United States."

Alternate Health announced the Company's 12-month projections in a press release on October 12, 2017, anticipating significant revenue from Q4 2017 to Q3 2018. A key driver of this growth will be CanaPass and its U.S. equivalents, like FlorPass. As the only system that connect medical cannabis patients with physicians and providers securely and transparently, Alternate Health's Blockchain ledger will assure compliance and decrease fraud in emerging cannabis markets across the United States.

At Devcon3, Alternate will be recruiting the top developers and meeting with potential partners to expand on two key priorities:

  1. Developing an application for the automated payment of cannabis using cryptocurrency for B2B cannabis purchases based on smart contracts for payments on a blockchain. By using an If-Then premise, this will ensure payments are automatically sent once a series of predetermined events has been achieved. For example, dispensaries could automatically generate a purchase order from a distributor once a product's inventory falls below a certain point, and payment for the product would be automatically released upon delivery.
  2. Developing a Blockchain ledger to track appropriate tax payments associated with the legal cannabis industry and providing a platform for licensed growers and retailers to exchange their cryptocurrency for cash to submit accurate, automatic tax payments. This ledger will be fully transparent to government officials and tax agencies to ensure proper, on-time payments from licensed cannabis entities.

"Now that Alternate Health's CanaPass is proven and operational in Canada this quarter, it's time to take a global approach to our business," says Dr. Murphy. "Alternate Health is committed to continuing development and evolution in this exciting space and looks forward to meeting the top programmers and business minds that Devcon3 has to offer."

Alternate Health's Blockchain ledger will confirm the patient's identity and age, document each legal anonymized sale in an unchangeable ledger, and verify the patient has an active marijuana recommendation from a licensed physician in strict medical states. The personal health records created on the CanaPass EMR will then be encoded and stored on the Blockchain with a private key that would grant access only to specific individuals.

In Canada where medical marijuana is federally legal and reimbursable by some health insurance plans, receipts of cannabis purchases and physician visits can be stored on Alternate Health's Blockchain and be automatically sent to insurance providers as proof-of-delivery for payment. The ledger can also be used for general cannabis management, such as supervising patient outcomes, regulation compliance, and storing product test results.

About Ethereum and the Devcon3 Conference

Ethereum is the protocol of choice for smart contract development. While smart contracts can be encoded on any blockchain, Ethereum is considered the most advanced for coding and processing smart contracts due to its unlimited processing capability. In the cannabis industry, smart contracts provide an unprecedented level of trust, transparency, safety and accuracy that is needed to ensure stability and continued growth in this sector.


About Alternate Health Corp.

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. This sophisticated cross-integration of the company's enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals (OTCMKTS:GWPRF), AXIM Biotechnologies Inc. (OTCMKTS:AXIM), Canopy Growth Corporation (TSE:WEED), and Aphria Inc. (TSE:APH). Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity. For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:

1.604.512.7122

Nancy Goertzen, CPIR

n.goertzen@alternatehealth.ca

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH CORP. PROJECTS $75 MILLION IN REVENUE

Toronto, ON, October 12, 2017 - Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTC:AHGIF), an international medical cannabis company that uses technology, research, and clinical services to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices, today announced its projected revenues for the next 12 months starting in Q4 2017.

"After a strong start to Alternate Health's 1st year as a public company, we are excited to release our projected revenues for the next year," says Dr. Michael Murphy, CEO of Alternate Health. "We have assembled a dedicated team of industry veterans and secured key assets across our four business pillars, which will drive significant revenues over the next 12 months."

AHG 12 Month Projections: Q4 2017 – Q3 2018*

Total Net Revenue: $75,083,000

Total EBITDA: $33,410,000

Date Net Revenue EBITDA
Q4 2017 $5,857,000 $1,671,000
Q1 2018 $14,491,000 $5,512,000
Q2 2018 $25,528,000 $11,026,000
Q3 2018 $29,207,000 $15,201,000


EBITDA represents Earnings Before Interest, Taxes, Depreciation and Amortization.

The Company's laboratory testing and services division, Alternate Health Labs, Inc. (‘AHL') will continue to provide strong revenue growth throughout the next 12 months. AHL has completed its transition from reference laboratory to become an independent clinical laboratory, focused on diagnostic and toxicology testing. Alternate Health was recently approved for its Medicare license and will be applying to bill insurers directly in Q4, opening up new revenue sources and higher net revenue per specimen.

Alternate Health predicts that its CanaPass Patient Management System will be a key driver of market growth starting in Q4 2017. CanaPass' patent pending blend of online marketplace and cloud-based electronic medical records technology was first launched in July 2017 and is expected to be deployed in all nine National Access Cannabis clinics across Canada by the end of Q4. Building on the official endorsement of the American Medical Marijuana Physicians Association (AMMPA), Alternate Health is adapting CanaPass to local regulations in the American medical cannabis market.

For a copy of the Company's Investor Deck including revenue projections click here:
Download Alternate Health Investor Deck

*With the recent approval of its Medicare license, the above projections assume that Alternate Heath Labs, Inc. continues to grow its rep base which refers physician patient blood and toxicology samples to our lab for testing. It also assumes maintaining and developing partner/consulting arrangements related to hospital referrals.  In addition, the projections assume the successful installation of CanaPass at National Access Cannabis Inc. ("NAC") in its nine clinics across Canada. NAC currently has over 10,000 patients utilizing its clinics and that number is expected to grow as additional clinics are added. It also has relationships with licensed Marijuana producers and earns fees from patients and licensed producers.  Alternate Health will share in those fees. Also, based on work with the AMMPA and state approved US licensed producers, these projections assume initial CanaPass software installation by users in three states providing capacity for transaction fees from an initial US customer base estimated to be 100,000 with significant growth potential in those and other states. Failing these assumptions, including a stagnant or shrinking rep base, lack of further hospital relationships, cessation of the relationships with NAC and the AMMPA these projections could be materially wrong. Associated risks include changing government regulations related to US federal marijuana laws and for clinical laboratories and Medicare reimbursement rates. Competition factors could also impact these projections. 

About Alternate Health Corp.

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) Alternate Health has established multiple arms-length operations within the medical cannabis industry, each of which drives consumers, data and strategic opportunities to the company's other verticals. This sophisticated cross-integration of the company's enterprises has positioned Alternate Health as one of the only cannabis companies that delivers consistent revenue and intellectual property without growing, manufacturing or distributing the cannabis plant. Through its software solutions, data analytics, and patented delivery systems, Alternate Health's goal is to be the global authority on scientific and clinical support for cannabis in regulated markets. Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:


Nancy Goertzen, CPIR

n.goertzen@alternatehealth.ca

1.604.512.7122

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations and revenue projections, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. This announcement contains information about the company's future plans and financial projections that have been prepared on the basis of assumptions as to future events which management expects to take place and the actions management expects to take as of the date the information is prepared. Past performance may not be indicative of future results. Therefore, no current or prospective investor should assume that the future performance of any specific investment, investment strategy, or product made reference to directly or indirectly in this document, or indirectly via link to any unaffiliated third-party website, will be profitable or equal to corresponding indicated performance levels.  The Company cautions that the EBITDA figures reported in this news release do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. Except as required by law, the Company does not assume any obligation to release publicly any revisions to forward-looking information contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.



ALTERNATE HEALTH INVITED TO PRESENT AT THE AMERICAN MEDICAL MARIJUANA PHYSICIANS ASSOCIATION'S ANNUAL CONFERENCE

TORONTO, Oct. 5, 2017 - Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTC:AHGIF), an international medical cannabis company that uses best-in-class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices, today announced that the company will present at the upcoming AMMPA Annual Conference just outside Orlando, Florida.

"Following the AMMPA's historic endorsement of Alternate Health's CanaPass Patient Management System, we are proud to announce the launch of FlorPass at the AMMPA Annual Conference," says Dr. Michael Murphy, CEO of Alternate Health. "FlorPass is the latest version of the CanaPass system, adapted to the legal and regulatory environment of medical cannabis in the state of Florida."

Alternate Health's Chief Legal Officer, George Mull, will be presenting on the importance of transparency and regulatory compliance in recommending medical cannabis. With an expected audience of hundreds of physicians, George Mull will demonstrate how FlorPass is a unique and powerful tool to combine the spheres of strong clinical oversight and strict legal compliance.

FlorPass's key feature is the way it connects patients, physicians and cannabis producers in one system, supporting transparent records of all recommendations, transactions and medical data. Alternate Health's recent addition of the Blockchain Ledger to the system gives FlorPass an unrivaled level of transparency and regulatory oversight across the industry.

"Our system offers physicians, patients and government officials the oversight and data they need to adapt to Florida's new medical cannabis regulations," says Dr. Murphy. "FlorPass is the perfect tool for Florida's medical cannabis community,"

AMMPA Annual Conferences attendees will have the chance to demo the software and see how FlorPass can assist doctors in improving medical cannabis patient outcomes at their practices. Representatives from Alternate Health will be available to answer questions about FlorPass and network with potential new users of the system.

AMMPA Annual Conference 2017

Who:
American Medical Marijuana Physicians Association

What:
Annual Conference, Presentations and Continuing Medical Education

When:
October 6-8, 2017

Where:
Hilton Orlando Lake Buena Vista
1751 Hotel Plaza Boulevard
Lake Buena Vista FL, 32830

The three-day conference is held annually by the AMMPA, offering doctors and medical professionals the opportunity to update and expand their knowledge of the regarding sophisticated diagnostic and practice guidelines, to share new ideas for evaluation and treatment techniques, and to increase the practitioner's knowledge and ability to act and advocate for patients within the current medical legislative and regulatory environment. Educational formats include lectures, PowerPoint presentations, panel discussions and Q&A sessions.

About Alternate Health Corp.

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals (OTCMKTS:GWPRF), AXIM Biotechnologies Inc. (OTCMKTS:AXIM), Canopy Growth Corporation (TSE:WEED), and Aphria Inc. (TSE:APH). Alternate Health is differentiated from other cannabis companies by its focus on ancillary services for patients, healthcare professionals and regulatory providers rather than selling a commodity.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:


Nancy Goertzen, CPIR

n.goertzen@alternatehealth.ca

1.604.512.7122

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH LAUNCHES FIRST EVER CANNABIS BLOCKCHAIN TRANSACTION LEDGER

Toronto, ON, September 27, 2017 - Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTC:AHGIF), an international medical cannabis company that uses best-in-class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices, today announced the rebranding of its CanaCard software to the CanaPass Patient Management System with the goal of integrating mobile technology and provide blockchain ledger for the purposes of transparency and accountability.

"The evolution of CanaPass is a natural step forward in Alternate Health's software development, as we continuously update and adapt the system to changes in technology," says Dr. Michael Murphy, CEO of Alternate Health. "CanaPass represents a shift from a card-based system to embrace advances in mobile and cloud computing, unlocking significant potential for growth. And using blockchain ledger creates the accounting necessary for both State and Federal governments to embrace our technology."

The CanaPass system is a cloud-based software platform that manages the end-to-end transactions involved with providing safe access to medical and recreational cannabis (where applicable) to eligible patients and customers. The database is accessible by the patient, certified doctors and licensed producers only linked through a seamless Health Insurance Portability and Accountability Act ('HIPAA') compliant ledger, and is used to monitor the individual patient and provide enhanced treatment recommendations, with a focus on improving patient outcomes. HIPAA compliance involves protecting access to health information such as patient records, treatment and operations. The HIPPA stipulates that patient data must be protected with secure networks and procedures to prevent people from accessing health care information without consent. The blockchain ledger represents the final missing ingredient to create full open accountability.

Through Alternate Health's recent agreement with National Access Cannabis (TSX:NAC), CanaPass is in the process of being deployed across Canada. The CanaPass system will launch in all nine NAC clinics starting in October, and will also be used in any new locations as NAC expands. The CanaPass system is also developed to support full compliance for the distribution and transactions for recreational cannabis.

"The CanaPass brand reinforces our leadership position in practice management and electronic records for controlled substances," says Dr. Murphy. "Alternate Health's commitment to providing the most advanced and up-to-date software solutions is just one of many reasons the American Medical Marijuana Physicians Association (AMMPA) has endorsed CanaPass with the open accountability for the administration of controlled substances. We expect CanaPass to begin to generate significant revenues in the fourth quarter."

About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of, and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The Company is headquartered in San Antonio, Texas, with operations in Los Angeles and Toronto.

Alternate Health resides in the cannabis sector along with companies like GW Pharmaceuticals (OTCMKTS:GWPRF), AXIM Biotechnologies Inc. (OTCMKTS:AXIM), Canopy Growth Corporation (TSE:WEED), and Aphria Inc. (TSE:APH). The difference with Alternate Health is their focus is on servicing regulatory providers as opposed to marketing a commodity.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:


Nancy Goertzen, CPIR

n.goertzen@alternatehealth.ca

1.604.512.7122

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.



AMERICAN MEDICAL MARIJUANA PHYSICIANS ASSOCIATION ENDORSES ALTERNATE HEALTH'S CANAPASS PATIENT MANAGEMENT SYSTEM

Toronto, ON, September 25, 2017 - Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTC:AHGIF)), an international medical cannabis company that uses best-in-class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices, today announced that the American Medical Marijuana Physicians Association (AMMPA) has endorsed the Company's CanaPass patient management software.

"AMMPA's commitment to physician advocacy means that we are always looking for products that will help increase compliance, decrease liability, and improve patient outcomes in the medial marijuana industry," says Dr. Orlando Florete, MD, President of the American Medical Marijuana Physicians Association. "We believe that CanaPass and its U.S. equivalents will be a benefit to physicians that recommend alternative medical treatments in a safe and legal environment."

Based in Clermont, Florida, AMMPA's mission is to support physicians and patients who utilize medical marijuana as a treatment alternative in the setting of a legally indicated diagnosis. With over 650 physician members, AMMPA is a leader in providing physicians with comprehensive support in education, compliance and legal advocacy.

"We are honored to receive AMMPA's recognition of the CanaPass system's unparalleled focus on transparency and compliance," says Jade Green, Vice-President, Sales and Marketing, at Alternate Health. "This endorsement represents another step forward as we aim to set the standard in cannabis-specific medical software across North America."

The CanaPass system is a cloud-based software platform that manages the end-to-end transactions involved with providing safe access to medical cannabis for eligible patients. CanaPass's key features include the ability to view a patient's purchase history and monitor a patient's response to cannabis products, allowing physicians to make recommendation adjustments to improve overall patient outcomes.

"We are excited to see one of Alternate Health's key technology assets receiving recognition from such an influential and respected organization of physicians," says Dr. Michael Murphy, CEO of Alternate Health. "The CanaPass system solves a number of challenges in the field of medical cannabis, setting us up for new opportunities in this rapidly developing sector."

A copy of the American Medical Marijuana Physicians Association official endorsement letter can be accessed via the link below.

https://alternatehealth.ca/docs/AMMPA_Endorsement.pdf

About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of, and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The Company is headquartered in San Antonio, Texas, with operations in Los Angeles and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:


Nancy Goertzen, CPIR

n.goertzen@alternatehealth.ca

1.604.512.7122

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.



ALTERNATE HEALTH CORP. IS RANKED 4th ON CANADIAN SECURITIES EXCHANGE IN ITS FIRST YEAR

Toronto, ON, September 21, 2017 - Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTC:AHGIF), an international medical cannabis company that uses best-in-class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices, today announced that the Company has been ranked fourth amongst its peers on the Canadian Securities Exchange's CSE 25 Index

"As the exchange has grown rapidly in terms of trading volumes and market capitalization, it is appropriate that we give market participants a benchmark that monitors the performance of our largest and most liquid issues," says Richard Carleton, CEO of the Canadian Securities Exchange. "As the 'Exchange for Entrepreneurs', we are proud of their success in the Canadian capital markets."

A subgroup of the CSE Composite Index, the new CSE25 index includes the top 25 securities by market capitalization contained in the composite index. Together, these companies account for over 50% of the weighting in the Composite Index and typically are stocks that attract the most trading volume.

"We are proud of our inclusion in the CSE25 Index and to be recognized among the top five performers on the Canadian Securities Exchange," says Dr. Michael Murphy, CEO of Alternate Health". "This is a sign of the Company's strong momentum as we push forward with our goal to be the global authority on scientific and clinical support for medical cannabis in regulated markets".

About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of, and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The Company is headquartered in San Antonio, Texas, with operations in Los Angeles and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:


Nancy Goertzen, CPIR

n.goertzen@alternatehealth.ca

1.604.512.7122

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.



ALTERNATE HEALTH CORP. WITHDRAWS CONSULTING AGREEMENT AND RESCINDS WARRANTS AND COMMON SHARES

Toronto, ON, September 6, 2017 - Alternate Health Corp. (the 'Company') (CSE: AHG) (OTC: AHGIF) today announced that it has withdrawn a previously agreed consulting agreement that was to provide ongoing international marketing, fundraising, and targeted awareness for and on behalf of Alternate Health Corp. and has been concluded amicably as the parties have elected to pursue other interests. Pursuant to the terms of the consulting agreement, the Company was to issue 150,000 common shares at a deemed price of $3.05 upon execution of the consulting agreement; the Company was to grant 750,000 warrants to purchase the Company's shares at a price of CAD$3.05 per common share for a period of 18 months from the date of issuance. In addition, the Company was to grant an additional 750,000 warrants, to purchase the Company's shares at a price of CAD$4.00 per common share; the effective date of the grants is June 14, 2017. As a result of the withdrawal, the agreements and related common shares and warrant issuances have been terminated, and all compensation contemplated in the agreement have been agreeably rescinded to treasury.


About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of, and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The Company is headquartered in San Antonio, Texas, with operations in Los Angeles and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:


Nancy Goertzen, CPIR

n.goertzen@alternatehealth.ca

1.604.512.7122


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements



ALTERNATE HEALTH CORP. ANNOUNCES ANNUAL GENERAL MEETING RESULTS

Toronto, ON, August 14, 2017 - Alternate Health Corp. (the 'Company') ) (CSE: AHG) (OTC:AHGIF) is pleased to announce that all of the resolutions put forth at the Company's Annual General Meeting of Shareholders (the 'Meeting') held on August 9, 2017 have been approved. In addition to the standard annual shareholder resolutions which include setting the number of directors, the election of the directors of the Company, and the appointment of BDO Canada, LLP, as auditors for the coming year, the Company's shareholders approved and ratified the Company's 15% rolling stock option plan, as amended and restated on August 4, 2017. A majority of votes cast, by disinterested shareholders, was received on this resolution.

At the Meeting, the following directors were elected; and directly after the meeting the Board of Directors appointed the following Officers:

Directors:

James Tykoliz
Jim Griffiths
Michael Murphy
Bernie Rice
Michael Klipper
Kristin Taylor

Officers:

Michael Murphy, Chief Executive Officer and Chairman
Jim Griffiths, Chief Financial Officer
Marcelin O'Neill, Chief Compliance Officer
Jade Green – Vice President, Sales and Marketing







Stock Options:

In connection with the news release disseminated on August 4, 2017, the Company wishes to update the number of options granted as 330,000 stock options exercisable at $2.90 per share for 5 years.


About Alternate Health Corp.

Alternate Health Corp. (CSE: AHG, OTCQB: AHGIF) is an international medical cannabis company that uses best in class software technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis/CBD value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The company is headquartered in Dallas with operations in Los Angeles, San Antonio and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:


Nancy Goertzen, CPIR

n.goertzen@alternatehealth.ca

1.604.512.7122


Byron Striloff

b.striloff@alternatehealth.ca

1.604.657.8400

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



Alternate Health Corp. Reports Second Quarter 2017 Financial Results
Second Quarter Revenue of $7.2 Million up 87% From the First Quarter

Dallas, Texas (Business Wire) - August 8, 2017- Alternate Health Corp. (Alternate Health) (CSE: AHG, OTC: AHGIF), an international medical cannabis/CBD company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices, today announced its results for the second quarter ending June 30, 2017. All dollar references in Canadian dollars unless otherwise noted.

Second Quarter 2017 Financial Highlights

  • Q2 Revenue of $7.2 million increased 87% compared to $3.9 million in Q1 of 2017 Revenue was Nil in Q2 of last year
  • Adjusted EBITDA of $25k compared to $1.4 million in Q1 of 2017 and Nil in Q2 2016
  • Net loss of $3.6 million compared to a loss of $0.6 million in Q1 of 2017 and up from a loss of $0.1 million in Q2 of last year.
  • Working capital of $7.5 million compared to $10.5 million in Q1 of 2017 and $0.5 million at year end 2016.

During the quarter, Alternate Health continued to invest in growth opportunities in its Laboratory, Life Sciences and Technology businesses, while effectively managing its cash resources for growth in its existing operations. It made significant investments in people and other key resources to support growth in all its business sectors but particularly in in its Laboratory business which saw revenue growth of $ 6.9 million in the quarter. Cash used for significant strategic capital investments in the quarter included $1.6 million in securities of National Access Cannabis, $506,000 in Life Sciences CBD delivery system licenses and Continuing Education programs as well as $438,000 in equipment.

Second quarter net loss of $3.6 million includes a $3.4 million non-cash charge relating to equity awards computed using fair market valuation modeling as required by accounting guidance. Additionally, the Company recognized a foreign exchange charge of $200,000 in the second quarter compared to a foreign exchange credit of $150,000 in the first quarter of 2017. This swing was due to currency exchange fluctuations between the Canadian dollar and the US dollar during the quarter which saw the strengthening of the Canadian dollar.

Note – Alternate Health Corp ("the Company") was formed in January 2017 from a reverse take-over of a privately held operating company, Alternate Health Inc. ("AHI"). Per the accounting guidance, the Company's current year quarterly operating statements are compared to the same prior year periods of AHI. Similarly, the Company's balance sheets for the current year quarter end periods are compared to the same prior year periods for AHI.

Management Commentary

We are very pleased with the second quarter results, especially the very significant growth in our lab business, said Dr. Murphy the Company's Chairman and CEO. "We are also delighted with our progress in our other business lines and the important initial deployment of our CanaCard practice management software in Canada."



Second Quarter 2017 Operational Highlights

  • Reached an agreement to launch CanaCard Patient Management System in National Access Cannabis (NAC) clinics across Canada. NAC operates ten clinics across Canada, with a specific focus on connecting patients with clear information on the legal treatment options available. This is a very strategic investment expected to impact the growth of our CanaCard business.
  • Announced strategic changes in the operational structure of its wholly-owned clinical laboratory, Alternate Health Laboratory, Inc. ("AHL") to maximize profitability while also positioning AHL to service a potentially larger base then currently available. AHL will be transitioning from a reference laboratory servicing hospital client to a full-service clinical laboratory providing toxicology, blood, and pharmacogenetics testing on samples sent directly to AHL by physicians and other healthcare providers.
  • Entered into an agreement to acquire the Neubauer Hyperbaric Neurological Center in Florida to be used to facilitate ongoing research and the study of CBD and. Hyperbaric Oxygen Treatment


Second Quarter 2017 Corporate Financial Summary

$ in Millions, except per share data or otherwise noted

2017

Second Quarter

First Half

 

Q1

2017

2016

Change

2017

2016

Change

Revenue

$3.9

$7.2

$ -

$7.2

$11.1

$0.1

$11.0

IFRS Net Loss

($0.6)

($3.6)

($0.1)

($3.6)

($4.9)

($0.2)

($4.7)

IFRS Net Loss Per Share

($0.02)

($0.07)

$ -

($0.07)

($0.09)

($0.01)

($0.08)

EBITDA(1)

($0.4)

($3.6)

($0.1)

($3.6)

($4.1)

($0.1)

($4.0)

EBITDA Margin

(11.0%)

(51%)

(245%)

194 pts

(37%)

(163%)

126 pts

Non-IFRS Adjusted Net Income (Loss)(2)

$1.1

$34k

($0.1)

$0.1

$1.1

($0.2)

$1.3

Adjusted EBITDA(2)

$1.4

$25k

($0.1)

$0.1

$1.4

($0.1)

$1.4

Adjusted EBITDA Margin

35.3%

0%

(245%)

245 pts

12%

(163%)

175 pts

 

(1)

Adjusted earnings before interest, taxes, depreciation a amortization

(2)

A reconciliation of IFRS to non-IFRS adjusted results is included in this press release and our Management Discussion and Analysis dated May 30, 2017 and available at www.sedar.com.   

 


About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The company is headquartered in the Dallas-Fort Worth Metroplex with operations in Los Angeles, San Antonio and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:


Nancy Goertzen, CPIR

n.goertzen@alternatehealth.ca

1.604.512.7122


Byron Striloff

b.striloff@alternatehealth.ca

1.604.657.8400

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH CORP. ANNOUNCES APPOINTMENT OF DR. MICHAEL MURPHY AS CEO

Toronto, ON, August 4, 2017 - Alternate Health Corp. (the 'Company') (CSE: AHG) (OTC:AHGIF) is pleased to announce the appointment of Dr. Michael Murphy to the position of CEO of Alternate Health Corp. Dr. Murphy will continue as the Chairman of the Board and will take on the role of CEO effective immediately.

Dr. Murphy has over 30 years of private practice in pain medicine, founding and building multiple ambulatory surgical centers, 2 large surgical hospitals, a medical office campus, an image center, physical therapy center and a large medical laboratory. He also helped found The Bank of San Antonio where he currently sits on the Board of Directors as well as a registered independent investment company. Murphy is the founder or Alternate Health Labs Inc. and in his CEO role will oversee its management as well as the Company's Medical Software and Life Sciences businesses with the support of Mr. Howard Mann who heads up the Company's Life Sciences subsidiary, Alternate Heath Inc..

We are also pleased to announce the appointment of Mr. James Griffiths as CFO effective August 4, 2017. Mr. Griffiths holds a Master in Business Administration, is a chartered accountant with over 35 years of experience in the real estate development and financing industries. Over his career he has facilitated over $2 billion in real estate sales and acquisitions and oversaw $2.5 billion in real estate loans. He is currently a director of Allied Properties Real Estate Investment Trust, Enssolutions Group Inc., and is President of KLC Capital Investment Corporation, which provides financial advisory services. Mr. Griffiths is a director of the Company and was its CFO from September 2015 thru February 2017.

We thank Dr. Jamison Feramisco for his recent service as CEO and his executive leadership on our key business units during the first half of 2017. He leaves in good standing to devote time and effort on his major interest, healthcare data analytics, with Apri Health Inc., a potential strategic partner for Alternate Health and a company in which we have made a convertible debenture investment.

The appointments of Dr. Murphy as CEO and Mr. Jim Griffiths as CFO highlight the strategic reorganization and consolidation of the management team as we enter the next phase of growth for Alternate Health.

We thank Mr. Michael English who has served as CFO through the first two quarters as well as Mr. Tom Bartlett who has served as COO during this time. We would also like to take this opportunity to acknowledge the contribution of Mr. Bryan Korba, President of Alternate Health, for his executive leadership following the launch of Alternate Health Corp. onto the CSE and the OTCQB in January of 2017 and through Q1 and Q2 of this year.

"We have appreciated the contribution of service and leadership from Dr. Feramisco, Mr. Michael English, Mr. Tom Bartlett and Mr. Bryan Korba over these past several months and wish each of them success in their future endeavours, says Dr. Michael Murphy."


About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The company is headquartered in the Dallas-Fort Worth Metroplex with operations in Los Angeles, San Antonio and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:


Nancy Goertzen, CPIR

n.goertzen@alternatehealth.ca

1.604.512.7122


Byron Striloff

b.striloff@alternatehealth.ca

1.604.657.8400

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH CORP. ANNOUNCES AMENDMENT TO ANNUAL GENERAL MEETING MANAGEMENT NOMINEES, SHARE ISSUANCE, AND STOCK OPTION GRANTS

Toronto, Canada, August 4, 2017 - Alternate Health Corp. (the 'Company') (CSE:AHG) (OTC:AHGIF) today announces that it wishes to withdraw the name of Jamison Feramisco as a management nominee for director at the Annual General Meeting (AGM).

Mr. Feramisco's term as a director will cease immediately before the election of directors at the AGM, in accordance with the Company's Articles and the Business Corporations Act (British Columbia).

The Company wishes the number of directors to be set at six, as proposed in the Information Circular for the AGM. In light of the foregoing and the withdrawal of Mr. Feramisco's name, the Company's management wishes to propose the name of a sixth director for election: Ms. Kristin Taylor. If a proxyholder has given no specific voting instructions, those proxies will be voted by management in favour of electing Ms. Taylor as a director. The Company has been advised by certain significant shareholders and directors of the Company who will attend the AGM in person, that they intend to vote for Ms. Taylor as a director.

SHARE ISSUANCE

The Company also announces that it has entered into various management and consulting agreements (the 'Agreements') with certain officers and consultants of the Company. Pursuant to the terms of one Agreement, the Company will grant an aggregate of 100,000 common shares at a deemed price of CAD$2.90 per common share. The share issuance will be subject to the required four months hold period legend, pursuant to the Policies of the regulatory authorities.

STOCK OPTIONS

The Company also wishes to announce that it has granted incentive stock options to certain directors, officers, and/or consultants of the Company for the right to purchase up to an aggregate of 270,000 common shares of the Company, exercisable at the price of CAD$2.90 per share for five years. The effective date of the grant of option is August 4, 2017. The stock options granted will be in accordance with the Company's Stock Option Plan and will have the required four months hold period legend, pursuant to the Policies of the CSE and regulatory authorities.


About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The company is headquartered in the Dallas-Fort Worth Metroplex with operations in Los Angeles, San Antonio and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:


Nancy Goertzen, CPIR

n.goertzen@alternatehealth.ca

1.604.512.7122


Byron Striloff

b.striloff@alternatehealth.ca

1.604.657.8400


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH CORP. ANNOUNCE STRATEGIC CHANGE TO ITS GROWING TESTING LABORATORY STRUCTURE

Toronto, ON July 3, 2017 - Alternate Health Corp (CSE:AHG) (OTC:AHGIF) today announced strategic changes in the operational structure of its wholly-owned clinical laboratory, Alternate Health Laboratory, Inc. ("AHL").  These changes will maximize profitability while also positioning AHL to service a potentially larger base then currently available.

AHL will be transitioning from a reference laboratory servicing hospital clients to a full-service clinical laboratory providing toxicology, blood, and pharmacogenetics testing on samples sent directly to AHL by physicians and other healthcare providers.  We believe this change in our business model will better position AHL for sustainable growth in a rapidly changing healthcare environment.

AHL has applied to become a participating provider with Medicare and will apply to other federal insurance carriers and commercial carriers to provide services to beneficiaries covered under their insurance plans.  By positioning our laboratory to bill directly from the payers, we eliminate massive third-party expenses and increase our revenue per sample. We are actively developing our physician referral base for federal and commercial samples.

We anticipate the transition to a full-service laboratory will take several months and may cause a decrease in AHL revenue during the third quarter, but we are embracing this change and making the necessary adjustments to move us forward in a more efficient and profitable manner.  We believe revenue will increase during the fourth quarter and continue as a larger, more secure source of revenue in the future.


About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The company is headquartered in the Dallas-Fort Worth Metroplex with operations in Los Angeles, San Antonio and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:


Nancy Goertzen, CPIR

n.goertzen@alternatehealth.ca

1.604.512.7122


Byron Striloff

b.striloff@alternatehealth.ca

1.604.657.8400

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH CORP. ANNOUNCES APPOINTMENT OF J. BERNARD RICE TO THE BOARD OF DIRECTORS

Toronto, ON June 30, 2017 - Alternate Health Corp (CSE:AHG) (OTC:AHGIF) is pleased to announce that J. Bernard Rice, has joined the Board of Directors of Alternate Health, a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and service delivery.

Mr. Rice is recognized as one of the world's leading experts in Information Technology. Mr. Rice has a wealth of enterprise business, experience and significant senior level relationships that are indispensable in developing many strategic partnerships. His Partner, General Wesley Clark and Mr. Rice are currently driving in a portfolio of companies with leadership capabilities in Cybersecurity, Green Energy, Medical technologies, Education and Real estate.

Mr. Rice began his career with IBM in sales and held various sales leadership positions until 1983 when he entered IBM's finance fraternity. Mr. Rice's work in business case structure and portfolio analysis led him to a role as IBM's Finance Director for Application Software in 1985. He was promoted several times such that by 1989 he was appointed Director of Finance, Planning and Administration for IBM's Southern Area. In that role, Mr. Rice was responsible for the staff functions of a $3 billion business and he was instrumental in positioning IBM's Southeast Region as the leader in billable services.

 

Mr. Rice became Chief Financial Officer and General Partner for the IBM Venture Capital Group in 1993 and then Vice President of Business development for IBM's Consumer Division in 1998. There he managed projects like IBM's partnership with Berkshire Hathaway and Hallmark for the development of its breakthrough on-line research and learning platforms.

Mr. Rice also served as Chief Executive Officer of Edmark Inc., the IBM subsidiary that developed innovative educational software for children. In 2000 Mr. Rice orchestrated the spin-off of IBM's education content assets into Riverdeep Inc and was instrumental in Riverdeep becoming the fastest growing educational software company in the nation. Today, Riverdeep has educational products in some 45,000 schools in over 20 countries.

Mr. Rice holds a B.A. from St. Anselm College (Manchester, New Hampshire) and a Masters in Business Administration in Marketing from Georgia State University. Mr. Rice also attended the IBM Presidents Program (a special Executive MBA program) at Harvard University.


About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The company is headquartered in the Dallas-Fort Worth Metroplex with operations in Los Angeles, San Antonio and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:


Nancy Goertzen, CPIR

n.goertzen@alternatehealth.ca

1.604.512.7122


Byron Striloff

b.striloff@alternatehealth.ca

1.604.657.8400

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH'S CANACARD CONTROLLED-SUBSTANCE MANAGEMENT SYSTEM TO LAUNCH IN ALL OF NATIONAL ACCESS CANNABIS' CLINICS ACROSS CANADA

TORONTO, June 14, 2017 - Alternate Health Corp (CSE:AHG) (OTC:AHGIF), an international medical cannabis company, announced today that the company has reached an agreement to launch its CanaCard Patient Management System in all of National Access Cannabis (NAC) clinics across Canada. Alternate Health uses best-in-class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices.

National Access Cannabis operates ten clinics across Canada, with a specific focus on connecting patients with clear information on the legal treatment options available. In recognition of NAC's leadership in Canadian medical cannabis, Alternate Health has made investments of close to $1,000,000 in the company. Alternate Health believes that this agreement creates a base for further expansion in the Canadian market, including the company's cannabinoid research and delivery systems.

"Alternate Health is taking a step forward in consolidating our leadership position in medical cannabis technology," says Dr. Jamison Feramisco, CEO of Alternate Health. "National Access Cannabis is a Canadian pioneer in medical marijuana and we are excited to see our technology help NAC benefit patients and generate revenue in a key area of both our businesses."

The CanaCard Patient Management System is a cloud-based platform that manages the end-to-end transactions involved with providing safe access to medical cannabis for patients across Canada. The database connects patients, certified doctors and licensed producers with a complete set of patient management tools. We ensure the secure storage of personal data, account balances, transactional volume and research data.

Alternate Health will install the system in each of National Access Cannabis' ten clinics across Canada and any new NAC clinics will operate with CanaCard in the future. Revenues will be generated for both NAC and Alternate Health from transaction fees charged on sales between patients and licensed producers of medical marijuana, compliant with Health Canada's rules and guidelines for medical cannabis in Canada.


About National Access Cannabis

National Access Cannabis operates in various cities across Canada and assists patients to improve their quality of life. Our Cannabis consultants guide patients through the process of obtaining the required legal documents to possess Medicinal Cannabis. We also connect patients with a suitable legal Licensed Producer approved by Health Canada. Every patient has access to extensive education and resources to ensure they are confident using their medication, and we also provide them with a convenient Medical Cannabis ID card.


About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The company is headquartered in the Dallas-Fort Worth Metroplex with operations in Los Angeles, San Antonio and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Contact

Mike English, CFO

972.378.3793


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH COMMENTS ON MARKETING ACTIVITIES

DALLAS, TX, June 8, 2017 - Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTC:AHGIF), an international medical cannabis company that uses best-in-class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices, commenced trading on its principal trading market, the Canadian Securities Exchange ("CSE") on January 24, 2017, and began quotation in the United States on the OTCQB on March 7, 2017

Since becoming a public company in January 2017, the Company has engaged third party providers (Finsbury, CFN Media, Stockhouse, Investing Media Solutions, Money Channel, Planet Microcap, See Thru Equity and Canada Newswire) to provide public relations, marketing or other related services.  Recently, the Company engaged an advertising and media firm to assist with a managed public awareness campaign, through paid third party agents and newsletter distributors.

On June 6, 2017, the Company received notice from the OTC Markets about promotional activities in relation to the Company and its common shares, including certain promotional newsletter emails.  The Company had not reviewed or seen these newsletters prior to publication and was not aware of the promotional nature of the materials.  Neither the Company nor its officers, directors, and to the best of its knowledge, its controlling shareholders have directly, or indirectly, authorized or been involved in any way with the creation of the promotional materials.

The Company has determined that certain statements included in these newsletters related to the Company and its business may be misleading and/or incomplete and readers should not place undue reliance on these newsletters.  The Company encourages investors to review its filings and disclosures made with Canadian securities regulators, available at www.sedar.com and as posted on the filings and disclosure page for AHGIF on the OTC Markets website at www.otcmarkets.com.

Since becoming a public company on January 19, 2017, the Company has completed two private placements of common shares. The first private placement of 2,914,354 common shares, priced at CAD$1.50, closed on January 20, 2017, with a statutory hold period that expired on May 21, 2017. The second private placement of 2,328,940 common shares, priced at CAD$3.25, closed on March 6, 2017, with a statutory hold period that expires on July 7, 2017.

Since becoming a public company, daily trading volumes have been minimal with volume increasing that the Company attributes to continued advancement of Alternate Health's business, recent earnings news releases and the expiry of the statutory hold period on May 21, 2017 of 2,914,354 common shares.

As disclosed in the Company's news release of April 17, 2017, Alternate Health granted 580,000 incentive stock options to directors, officers and consultants of the Company at an exercise price of CAD$4.00 per common share, and granted an aggregate of 867,544 warrants to officers of the Company at an exercise price of CAD$3.91 per common share.  An officer of the Company acquired 13,333 common shares on May 23, 2017, in a private purchase and sale transaction. In accordance with the rules and policies of the CSE, the Company has not issued convertible securities (warrants or options) below current market price.


About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The company is headquartered in the Dallas-Fort Worth Metroplex with operations in Los Angeles, San Antonio and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Contact

Mike English, CFO

972.378.3793


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH – THE FIRST CANNABIS COMPANY TO REPORT ADJUSTED EBITDA IN INITIAL FIRST QUARTER

DALLAS, TX, June 7, 2017 - Dr. Jamison Feramisco — CEO of Alternate Health Corp (CSE:AHG) (OTC:AHGIF), an international medical cannabis company that uses best-in-class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices — today congratulated staff, management and investors on reaching the positive cash flow milestone in the Company's first quarter of operation..

"The pace of growth in this company is very promising and I am truly impressed at how far we all have come in less than three months of operations," says Dr. Feramisco. "We are proud to be a profitable medical cannabis company, building shareholder value on real revenues and strategic investments – not just speculation. We are eager to demonstrate continued growth for the rest of 2017 and beyond."

Alternate Health is a fully integrated medical cannabis company, with operations divided among three key business pillars: laboratory services; medical software and regulatory compliance technology, cannabinoid therapy research education; production and delivery systems. In the first quarter, the majority of revenue came from Alternate Health's clinical laboratory testing, through its subsidiary Alternate Health Labs.

The Company generated $3.87 million in revenue in Q1, with operating expenses totalling $5.04 million. A considerable portion of these expenses were non-recurring, share-based sales incentives targeted at its rapidly growing laboratory business. To better reflect the financial results of the Company in its Q1 earnings release, Alternate Health reported Non IFRS measures including Adjusted (normalized) Net Income of $1.1 million or $0.03 per share and Non IFRS Adjusted EBITDA of $1.4 million as defined in its May 30th press release.

"Our success this quarter proves there's a high demand for our services and that we have the commitment and capability to meet that demand," says Dr. Feramisco. "We expect our software and education businesses to begin generating revenues next quarter, with our cannabinoid research and delivery system business following up in the third and fourth quarters."


About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The company is headquartered in the Dallas-Fort Worth Metroplex with operations in Los Angeles, San Antonio and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Contact

Mike English, CFO

972.378.3793


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH LAUNCHES A CANNABIS/CBD LARGE-SCALE CLINICAL STUDY ON POST-TRAUMATIC STRESS DISORDER (PTSD) FOR VETERANS

Toronto, ON, June 6, 2017 Alternate Health Corp. (CSE:AHG, OTC:AHGIF)), a diverse healthcare company revolutionizing patient care and research through compliance and technology in the emerging medical cannabis industry, is delighted to announce the upcoming launch of a new clinical study on the effects of Cannabidiol (CBD) in the treatment of veterans suffering from Post-Traumatic Stress Disorder (PTSD). Veterans' activist, Wesley Clark Jr., who himself served in the US Military, will lead the study beginning in June 2017.

"Cannabis is the treatment for PTSD," says Wesley Clark Jr., leader of the initiative. "This study will finally demonstrate irrefutable evidence, forcing the FDA to make a change for the better."

Alternate Health will conduct the PTSD study at its newly acquired Neubauer Center in Lauderdale-By-The-Sea, Florida, with the help of veterans suffering the effects of PTSD. The study will research the results of CBD administered through Alternate Health's delivery systems technology, building on the company's research assets. The company expects the results to bolster support and awareness of CBD in the medical community, with possible scientific breakthroughs forming the potential basis of new technology and patents.

Wesley Clark Jr.'s father, General Wesley Clark joined Alternate Health's Board of Directors in April 2017. A retired U.S. Army General and NATO Commander, General Clark shares his son's advocacy for veterans' health, from acute injuries to psychological trauma.

"Throughout my son's career, he has always been a strong proponent of veterans' rights and the anecdotal evidence of the treatment of PTSD with cannabis," says General Wesley Clark Sr. "We both look forward to corroborating this evidence with hard science."

Alternate Health and the Neubaurer Center previously collaborated on the successful Zika Virus Symptom Study, researching the use of CBD in treating patients suffering from the chronic effects of post-viral infection.

"Through this study, Alternate Health has the opportunity for substantial contribution to those who suffer from PTSD. We are honored to provide support for our Veterans and are eager to apply and study what we have learned about CBDs in other fields of medicine toward treating PTSD," says Dr. Jamison Feramisco, CEO Alternate Health.


About Wesley Clark Jr.

Wes was born in Jacksonville, Florida while his dad was in Vietnam. He spent four years in the military himself, and now resides in Los Angeles, California where he works as a screenwriter, and occasionally guest hosts on The Young Turks progressive internet show.


About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and research in the emerging medical cannabis industry. With American Medical Association-approved educational programs, software and patented delivery medical systems, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. In leveraging the company's assets in exclusive patents and partnerships, Alternate Health's goal is to be the global authority on the science, manufacturing and delivery methods for cannabidiol (CBD) and other cannabinoids.

Contact

Graham Buck: Graham.Buck@finsbury.com

Alex Kovtun: Alex.Kovtun@finsbury.com


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH ANNOUNCES NOTICE OF CHANGE OF AUDITOR

Toronto, ON, June 2, 2017 Alternate Health Corp. (CSE:AHG, OTC:AHGIF)wishes to announce that its Board of Directors have approved a change of the Company's auditors from Scarrow Yurman & Co. Professional Corporation ("Scarrow") to BDO Canada LLP ("BDO").

At the request of the Company, Scarrow has resigned as auditor of the Company effective May 23, 2017. The Audit Committee and the Board of Directors of the Company have appointed BDO as the successor auditor in their place effective May 23, 2017. The Company has sent a Change of Auditor Notice (the "Notice") to each of Scarrow and BDO, and has received a letter from each addressed to the securities commissions in each of British Columbia, Alberta, and Ontario (the "Commissions") stating they agree with the information contained in the Notice. A copy of each letter from Scarrow and BDO addressed to the Commissions will be filed on SEDAR with a copy of the Notice.

There were no disagreements or unresolved issues with Scarrow on any matter of audit scope or procedure, accounting principles or policies, or financial statement disclosure. It is the Company's opinion that there have been no reportable events, (as defined in National Instrument 51-102 (Part 4.11)) between the Company and Scarrow and Scarrow did not have any reservation in their auditors' report for the financial statements for the Company's last two fiscal years or for any period subsequent to the date the most recent audit report was issued and preceding the date hereof.

Alternate Health's CEO, Dr. Jamison Feramisco stated: "I would like to express our sincere gratitude to Scarrow on behalf of the shareholders and the board of directors, and we look forward to working with BDO going forward".


About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and research in the emerging medical cannabis industry. With American Medical Association-approved educational programs, software and patented delivery medical systems, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. In leveraging the company's assets in exclusive patents and partnerships, Alternate Health's goal is to be the global authority on the science, manufacturing and delivery methods for cannabidiol (CBD) and other cannabinoids.

Contact

Graham Buck: Graham.Buck@finsbury.com

Alex Kovtun: Alex.Kovtun@finsbury.com


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



Alternate Health Corp. Reports First Quarter 2017 Financial Results.

Company Generates Revenue of $3.9 Million and Adjusted EBITDA of $1.4 Million – (35 Percent) During Its First Quarter as an Operating Public Company

Dallas, Texas(Business Wire), May 30, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF), an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices, today announced its results for the first quarter ending March 31, 2017.All dollar references in Canadian dollars unless otherwise noted.

First Quarter 2017 Financial Highlights

  • Revenue of $3.9 million compared to Nil in Q1 of last year
  • Adjusted EBITDA of $1.4 million compared to Nil in Q1 2016
  • Net loss of $0.6 million, up from a loss of $0.1 million in Q1 of last year
  • Working capital of $10.5 million, up from $0.5 million at year end 2016
  • Total assets of $30.9 million, up $28.6 million from year end 2016
  • The company ended the quarter with $11 million in cash on hand and $0.5 million in debt

Revenue for the quarter was driven by strong performance from Alternate Health Labs, a clinical laboratory acquired in January of this year. The net loss of $0.6 million was in part due to $1.6 million of non-recurring, non-cash expense. We raised $11.1 million in new capital during the first quarter and generated $0.2 million cash from operating activities. We also placed $1.0 million in strategic partner investments.

For the first quarter 2017, Net loss per share (Per International Financial Reporting Standards or "IFRS") was $0.02 and non-IFRS fully diluted earnings per share was a positive $0.03. Adjusted net income was $1.1 million compared to negative $0.1 million for the same period last year.

Note – Alternate Health Corp ("the Company") was formed in January 2017 from a reverse take-over of a privately held operating company, Alternate Health Inc. ("AHI"). Per the accounting guidance, the Company's first quarter operating statement ending March 31, 2017 is compared to the first quarter 2016 of AHI. Similarly, the Company's balance sheet at March 31, 2017 is compared to the December 31, 2016 balance sheet for AHI.


Adjusted EBITDA Margin 35.3% - % 35.3 pts

(1) Adjusted earnings before interest, taxes, depreciation and amortization

(2) A reconciliation of IFRS to non-IFRS adjusted results is included in this press release and our Management Discussion and Analysis dated May 30, 2017 and available at www.sedar.com

About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and research in the emerging medical cannabis industry. With American Medical Association-approved educational programs, software and patented delivery medical systems, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. In leveraging the company's assets in exclusive patents and partnerships, Alternate Health's goal is to be the global authority on the science, manufacturing and delivery methods for cannabidiol (CBD) and other cannabinoids.

Contact

Graham Buck: Graham.Buck@finsbury.com

Alex Kovtun: Alex.Kovtun@finsbury.com


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements. The Company cautions that the EBITDA and adjusted Net Income figures reported in this new release do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers.


Read Entire Press Release...

Alternate Health Announces Completion of Initial Study to Treat Zika Virus Symptoms with Hemp-Derived Cannabinoid.

TORONTO – May 16, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF), a diverse healthcare company revolutionizing patient care and research through compliance and technology in the emerging medical cannabis industry, announced today the completion of its initial study to demonstrate the effectiveness of cannabinoid in treating chronic post-Zika virus symptoms.

The study, conducted at the Neubauer Hyperbaric Neurologic Center, evaluated the effectiveness of combining treatment with hyperbaric oxygen (HBO) and industrial hemp-derived cannabinoid to alleviate the rare but debilitating chronic post-Zika infection symptoms of pain, fatigue, anxiety, depressive state, and loss of appetite

The Zika virus is a flavivirus transmitted by mosquitos, and over the past 10 years has caused infection in more than 50 countries worldwide. Zika has been declared a pandemic and is considered a Public Health Emergency by the World Health Organization. The Centers for Disease Control and Prevention (CDC) has confirmed there is scientific consensus that Zika causes birth defects, and reports have linked its infection to an infrequent but serious neurological condition, Guillain-Barré Syndrome.

Although acute Zika infection is usually self-limiting, some patients can experience prolonged periods of severe fatigue, joint pain, loss of appetite, anxiety, depressive state, and lethargy after clearance of acute viral symptoms. It is these symptoms in this subset of Zika-infected patients that Alternate Health evaluated in its initial cannabinoid-based, Institutional Review Board (IRB) approved research study.

All 10 patients enrolled in the study demonstrated a significant improvement in their subjective symptoms in less than a month of dual therapy with the Alternate Health Corporation's proprietary hemp-derived sub-lingual dissolvable cannabinoid tablet combined with hyperbaric oxygen treatments.

"The initial results suggesting symptomatic improvement of post-Zika infection-related symptoms by combining cannabidiol – a known anti-oxidant and anti-inflammatory agent – with hyperbaric oxygen is extremely exciting," said Dr. Jamison Feramisco, CEO, Alternate Health. "Although this small study will need to be expanded and reproduced, it demonstrates the vast potential of cannabinoid and medical cannabis therapy to have broader applications for patients suffering from various disease states."

Alternate Health plans to expand its support of clinical trials at the Neubauer Center with the use of its hemp-derived cannabinoid products including sub-lingual dissolvable tablets to treat symptoms of other post-viral infections and conditions including Post-Traumatic Stress Disorder (PTSD) and Chronic Traumatic Encephalopathy (CTE)


About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and research in the emerging medical cannabis industry. With American Medical Association-approved educational programs, software and patented delivery medical systems, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. In leveraging the company's assets in exclusive patents and partnerships, Alternate Health's goal is to be the global authority on the science, manufacturing and delivery methods for cannabidiol (CBD) and other cannabinoids.

Contact

Graham Buck: Graham.Buck@finsbury.com

Alex Kovtun: Alex.Kovtun@finsbury.com


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH CORP REPORTS FULL YEAR 2016 FINANCIAL RESULTS

DALLAS, TEXAS – May 8, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) )), a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and research in the emerging medical cannabis industry, today announced its results for the full year ending December 31, 2016.

Dr. Jamison Feramisco, CEO of Alternate Health, said: "Our activities in 2016 set the foundation for the company to fully activate its operations in 2017. We successfully completed our share exchange agreement with Alternate Health Inc., which became a wholly-owned subsidiary of the company, and received approval to list our shares on the Canadian Securities Exchange ("CSE") with trading commencing on January 24, 2017. We also began to develop relationships across our businesses that led to agreements which closed in early 2017 including a lab development agreement with Dr. Michael Murphy to establish a 17,000 sq ft toxicology laboratory in San Antonio, Texas. The facility has the capacity to process up to 70,000 urine and blood samples per month and sufficient space to double its processing capacity."

Dr. Feramisco continued: "We've built on our progress in 2016 by announcing numerous developments in Q1 of 2017 that strengthen Alternate Health's financial and business profile. First, we improved the company's liquidity by closing two private placements for net proceeds of $11.3 million and listing our shares on the OTC bulletin board exchange. Second, we expanded our Board of Directors and management team to bring additional clinical corporate expertise in the oversight of Alternate Health's emerging medical operations. Third, we closed eight acquisitions, licenses or strategic investments that strengthen the Alternate Health's position in key markets and provide new growth opportunities. We're excited with our progress year-to-date and looking forward to providing updates on our performance in the coming months."


Full Year 2016 Compared to Full Year 2015:

  • Sales were $0.2 million compared to $0.2 million.
  • Operating expenses were $1.7 million compared to $0.4 million.
  • Net loss was $1.8 million, or $0.06 per diluted share, compared to a net loss of $0.2 million, or $0.01 per diluted share.
  • The 2016 net loss included a one-time charge of $0.7 million for the reverse acquisition transaction of Alternate Health Corp. and listing on the Canadian Securities Exchange.

Liquidity and Capital Resources:

  • The Company concluded the quarter ended December 31, 2016, with $570,003 in cash and cash equivalents as compared to $429,836 as of December 31, 2015. At December 31, 2016, the Company had working capital of $455,397.
  • In the first quarter of 2017, the Company closed two private placements for net proceeds of $11.3 mil. Additionally, share purchase warrants exercised in the first quarter generated proceeds of $627,501. Together these proceeds put the Company in a strong working capital position.
  • The Company has dual-listed its shares on the Canadian Securities Exchange ("CSE") and on the OTC bulletin board ("OTC") to improve the stock's liquidity.
  • Management, directors, and insiders of the Company currently own approximately 30 million common shares (58% of the current shares outstanding) and are committed to building long term shareholder value for the benefit of all its stakeholders.


About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Contact

Graham Buck: Graham.Buck@finsbury.com

Alex Kovtun: Alex.Kovtun@finsbury.com


Cautionary Disclosure Regarding Forward-Looking Statements

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This press release may contain certain forward-looking statements within the meaning of applicable Canadian and United States securities laws. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "may," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plans," "projects," "believes," "estimates," "confident" and similar expressions are used to identify these forward-looking statements. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements. Except as required by law, Alternate Health Corp. undertakes no obligation to update these forward looking statements.


ALTERNATE HEALTH CORP

Consolidated Statements of Loss and Comprehensive Loss

For the years ended December 31, 2016 and 2015



2016

2015


Revenue



License revenue

$ 183,398

$ 167,496

Miscellaneous income

148

59



183,546


167,555

Operating expenses



Advertising and promotion

13,428

-

Amortization

2,465

2,426

Amortization of intangible assets

93,635

73,219

Bank charges and interest

3,129

3,483

Business development

106,539

-

Consulting fees (recovery)

173,057

(8,083)

Interest on longterm liabilities

67,275

22,548

License fee expense

1,248

5,583

Office and general

45,764

26,838

Professional fees

160,233

108,796

Rent

115,757

121,848

Salaries and related benefits

40,170

40,170

Sharebased compensation

818,100

-

Travel

24,394

4,017



1,665,194


400,845


Loss before undernoted items and income taxes


$ (1,481,648)


$ (233,290)


Other expenses



Reverse acquisition transaction cost

107,919

-

Listing expense

594,900

-



702,819


-


Loss before income taxes


(2,184,467)


(233,290)

Income taxes

431,220

-


Net and comprehensive loss


$ (1,753,247)


$ (233,290)


Loss and comprehensive loss (basic and diluted) per share


(0.0564)


(0.0079)


Average weighted number of common shares outstanding (basic and diluted)


31,069,949


29,476,096



ALTERNATE HEALTH TO ACQUIRE FLORIDA-BASED NEUBAUER HYPERBARIC NEUROLOGICAL CENTER FOR ADVANCED CANNABINOID TESTING AND CLINICAL STUDY

PLANO, TEXAS – May 5, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) )), a diverse healthcare company revolutionizing patient care and research in the emerging medical cannabis industry, announced an agreement to acquire Neubauer Hyperbaric Neurological Center (NHNC) in Lauderdale-By-The-Sea, Florida, a pioneer and national leader in neurological disorder research and treatment.

Through this acquisition, Alternate Health will be positioned to be a major player in the Florida healthcare market, which is the third most populous state and holds the largest proportion of elderly residents in America. Alternate Health plans to leverage the decades of research, therapeutics, and expertise of the Neubauer Center to expand novel care delivery models and to perform clinical trials.

"Following Florida's vote last year to legalize medical cannabis, there are countless new opportunities for cannabinoid research and treatment across the state, including the hemp-derived Cannabidiol (CBD) compounds that we are focused on," said Dr. Jamison Feramisco, CEO, Alternate Health Corp. "The Neubauer Center acquisition strengthens our goal to put patients in charge of their healthcare options, while opening up new revenue streams in untapped markets."

Founded in 1972 by world-renowned physician Dr. Richard A. Neubauer, the Neubauer Hyperbaric Neurological Center was South Florida's first Hyperbaric Oxygen Treatment (HBOT) clinic and research facility. For 45 years, the Center has obtained a global reputation as the leader in HBOT research for the treatment of neurological disorders and other illnesses. The late Dr. Neubauer's family continues to operate the clinic.

Alternate Health and the Neubauer Center are currently collaborating on clinical studies researching the use of Cannabidiol compounds in treating patients suffering from chronic fatigue and persistent pain following the Zika virus infection. Concurrent with the acquisition, Alternate Health plans on both continuing the study of CBD and HBOT treatments in patients suffering from chronic post-flavivirus signs and symptoms and also in other fields of neurologic and mental health research.


About the Neubauer Hyperbaric Neurological Center

Having treated patients since 1972, Neubauer Hyperbaric Neurologic Center is a pioneer in the use of HBOT for neurological conditions in the Greater Miami Area. The results of founder Dr. Neubauer's scientific studies (through the Center) have been published in a variety of respected medical journals, including Lancet and the Journal of the American Medical Association.


About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Contact

Graham Buck

Graham.Buck@finsbury.com


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



LEADING MEDICAL CANNABIS RESEARCH COMPANY ALTERNATE HEALTH CORP. TO PRESENT AT PLANET MICROCAP SHOWCASE 2017

PLANO, TEXAS – April 25, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) ), a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and research in the emerging medical cannabis industry, will present a business update at the Planet MicroCap Showcase conference in Las Vegas at 9 a.m. PT on Thursday, April 27, 2017.

Stock Options

The Company also wishes to announce that it has granted incentive stock options to certain directors, officers, and/or consultants of the Company for the right to purchase up to an aggregate of 580,000 common shares of the Company, exercisable at the price of CAD$4.00 per share for five years. The effective date of the grant of option is April 14, 2017. The stock options granted will be in accordance with the Company's Stock Option Plan and will have the required four months hold period legend, pursuant to the Policies of the CSE and regulatory authorities.

Dr. Jamison Feramisco, CEO of Alternate Health, will lead the presentation and also be meeting with investors one-on-one at the conference. Alternate Health is among the top performing medical cannabis companies in the world today. With American Medical Association-approved educational programs, software and patented delivery medical systems, Alternate Health Corp is positioned for rapid growth. To schedule an in-person meeting, contact Robert Kraft, editor-in-chief of StockNewsNow.com, the conference organizer, at 424-227-9018 or rkraft@snnwire.com. Visit www.PlanetMicroCapShowcase.com for more information.

The Planet MicroCap Showcase is a conference that brings together promising companies and the top dealmakers in microcap finance for three days of company presentations, one-on-one meetings, and networking.


About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Contact

Graham Buck

Graham.Buck@finsbury.com


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH CORP. ANNOUNCES WARRANTS AND STOCK OPTION GRANTS

PLANO, TEXAS – April 17, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) today announced that it has entered into various employment and management agreements (the 'Agreements') with certain officers of the Company. Pursuant to the terms of the Agreements, the Company will grant an aggregate of 867,544 warrants to purchase AHC shares at a price of USD$2.93 or CAD$3.91 per common share for a period of five years from the date of issuance. The effective date of the grants is April 14, 2017.

Stock Options

The Company also wishes to announce that it has granted incentive stock options to certain directors, officers, and/or consultants of the Company for the right to purchase up to an aggregate of 580,000 common shares of the Company, exercisable at the price of CAD$4.00 per share for five years. The effective date of the grant of option is April 14, 2017. The stock options granted will be in accordance with the Company's Stock Option Plan and will have the required four months hold period legend, pursuant to the Policies of the CSE and regulatory authorities.


About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Contact

For further information, please contact Jim Griffiths at 416-607-5757


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



GENERAL WESLEY CLARK JOINS ALTERNATE HEALTH CORP. BOARD OF DIRECTORS.

PLANO, TEXAS – April 10, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) today announced that General Wesley K. Clark, former NATO Supreme Allied Commander, has joined the Board of Directors of Alternate Health, a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and service delivery. General Clark will assist and advocate for the company in its work to develop new treatments for patients suffering from post-traumatic stress disorder (PTSD).

Dr. Jamison Feramisco, CEO of Alternate Health said: "We are honoured that General Clark has joined the Board. As one of our country's most decorated public servants and a champion of the health of our veterans, General Clark will bring critical energy and resources to Alternate Health's work."

General Clark said: "Over my career, I've seen thousands of veterans return home each year with medical issues and ailments ranging from acute injuries to ongoing PTSD. We must explore innovative options for treating these and other debilitating conditions, and Alternate Health is on the frontlines of this effort. I'm looking forward to working with them to address veterans conditions and improve the lives of many Americans and international citizens."

General Clark served a distinguished career in the U.S. Army and rose to a four-star general as NATO's Supreme Allied Commander. Since retiring from the military in 2000, he has served in several capacities in the private sector and has chaired several public and private companies in the energy, banking and business services field. In addition to being a noted author and political commentator, he graduated first in his class at West Point and completed degrees in Philosophy, Politics and Economics at Oxford University as a Rhodes scholar. Among his awards are the Presidential Medal of Freedom, the Silver Star, Purple Heart and honorary knighthoods from the United Kingdom and the Netherlands.


About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Contact

For further information, please contact Graham Buck
Email: Graham.Buck@finsbury.com Phone: 416-607-5757


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH CORP. (CSE:AHG) (OTC: AHGIF) ANNOUNCED BOARD RESTRUCTURING AND APPOINTING A NEW CEO AND CHAIRMAN.

PLANO, TEXAS – April 5, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) today announced that it has named Dr. Jamison Feramisco as CEO (current AHC Director) and Dr. Michael Murphy as Chairman of the Board of Directors. These appointments represent significance in bringing additional clinical corporate expertise in the oversight of Alternate Health's emerging medical operations.

Dr. Feramisco is an M.D.,Ph.D., and is a graduate of the University of Texas at Southwestern Medical School. He is trained in both Internal Medicine and Dermatology and conducted his thesis research in the labs of Nobel Laurates Drs. Michael Brown and Joseph Goldstein MD, earning a Ph.D. degree in Molecular Genetics and Biochemistry. Dr. Feramisco brings Alternate Health a high level f experience and success in transforming corporate growth to profitability, strategic mergers and acquisitions, regulatory oversight and dynamic healthcare innovation across medical technology, digital health, big data analytics, and clinical services.

Dr. Michael Murphy currently manages the Alternate Health Clinical Laboratories and is the majority interest shareholder in Clover Trail LLC, a foundational partner of Alternate Health. Dr. Murphy is a M.D. specializing in Anesthesiology and Interventional Pain Management with a focus on alleviating chronic pain. He holds a very successful track record in acquiring and managing several medical service practices, clinics and Ambulatory Surgery Centers. He has also served on the Boards of various financial institutions. His wealth of experience and knowledge in laboratory operations, management, and regulatory compliance will a serve key function in supporting Alternate Health's business.

Alternate Health would also like to announce the resignation of Bryan Korba as Chairman, CEO and Director. Mr. Korba was hired to transition Alternate Health into a public listing, and to recruit and engage a suitable management team to grow the company.

"We are thrilled with the substantive work that Mr. Korba has done for Alternate Health thus far," said Dr. Jamison Feramisco, CEO. "He has provided a strong foundation by which myself and the Board can further to grow and expand the services of the company. We have requested that Bryan continue his contributions and stay with us as President of Alternate Health."


About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Contact

For further information, please contact Jim Griffiths at 416-607-5757


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH CORP. SETTLES DEBT

PLANO, TEXAS – March 17, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) (the "Company")announces that it has entered into a debt settlement agreement with the holder of a secured promissory note in the amount of USD$1,993,750. The debt was resulting from the Company's purchase of a 20% interest in Clover Trail Capital LLC as announced in the Company's news release of March 8, 2017. The Company has agreed to issue 800,387 common shares at a deemed price of $3.315 per common share to MLM Heritage Trust in consideration of extinguishment of the debt. The shares will have a four month hold period under Canadian securities laws.

Bryan Korba, Alternate Health's CEO indicated, "We are delighted to have reached this agreement because this will eliminate the associated interest expense and free up future cash flows to fund our growth strategy".


About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Contact

Jim Griffiths

Director of Investor Relations

416-607-5757


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



Alternate Health Announces US Listing On the OTC, And The Closing Of An Additional $7.5 Million In Funding

PLANO, TEXAS – March 10, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) (the "Company"), Alternate Health announced today that it has listed its shares for trading on the OTC bulletin board under the ticker symbol AHGIF, joining other top medical cannabis companies like Canopy Growth Corporation (TSX:WEED.TO) and GW Pharmaceuticals (NASDAQ:GWPH) in the largest cannabis market in the world.

Yesterday, Alternate Health also announced the closing of its recent capitalization of $7,569,055, less a finder's fee of $259,330.50. The company issued 2,238,940 common shares at a price of $3.25 Canadian ($2.50 US). The company currently has an on-hand cash position of over $12 million, all common shares issued under this private placement have a 4-month hold period in accordance with regulators and expiring July 7, 2017. Finders fees will be paid as permitted by the CSE policies and applicable securities laws.

"We are very excited to introduce the Alternate Health companies to American shareholders, as we have tremendous business interests in the US through our labs and technologies, as well as a growing suite of patented pharmaceutical delivery systems for medical cannabis," said Bryan Korba, CEO of Alternate Health Corp. "Our laboratory business is very profitable and that serves to fund development of our software and technology, as well as conducting research and obtaining the approvals necessary for our patented delivery systems."

Alternate Health (https://youtu.be/HX_qGSlIBjA) will continue to leverage its strengths to grow while conducting ongoing clinical studies that demonstrate the effectiveness of our products and our unique, patented medical cannabis delivery systems.

Through ongoing research and testing, Alternate Health will demonstrate its market leading position in this emerging sector of Healthcare.


Contact

Jim Griffiths

Director of Investor Relations

416-607-5757


About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.



Alternate Health Corp. Announces Closing of a $7.5M Non-Brokered Private Placement

PLANO, TEXAS – March 9, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) (the"Company") is pleased to announce that it closed on March 6, 2017, a non-brokered privateplacement with gross proceeds of CAD$7,569,055 less finder's fees of CAD$259,330.50.

The Company issued 2,328,940 common shares at a price of CAD$3.25 (USD$2.50) per share.All common shares issuable under the private placement have a four-month hold period inaccordance with securities laws, expiring on July 7, 2017. Finder's fees will be paid as permittedby CSE policies and applicable securities laws.

Alternate Health Corp. intends to use the proceeds of the private placement for generalworking capital purposes and continued acquisition and investment activities in the growingmedical cannabis industry and as it leverages its expertise in technology to revolutionize patientcare and service delivery.


Contact

Jim Griffiths

Director of Investor Relations

416-607-5757


About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.



Alternate Health Acquires Stake in Clover Trail Capital LLC Acquisition Includes Partial Ownership of Sun Clinical Laboratories

PLANO, TEXAS – March 8, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) (the "Company"), a diversified healthcare services company that uses its expertise in technology to revolutionize patient care and service delivery, announced today that it has reached an arms-length agreement to acquire a 20 percent interest in Clover Trail Capital LLC ("Clover Trail"), a Texas-based investment company. The acquisition is valued at US $5.5 million.

Clover Trail's investments include a comprehensive laboratory, performing complex lab studies for both toxicology and blood, servicing hospital groups, private insurance groups and large clinics. The acquisition gives Alternate Health Corp. an ownership in Sun Clinical Laboratories LLC, which is 40 percent owned by Clover Trail, and currently refers toxicology and blood samples to the Company's subsidiary Alternate Health Labs, Inc.

Alternate Health Corp. has operations in the United States and Canada. In addition to laboratory services, it is a leader in proprietary software applications for the medical industry. "We are delighted to be joining forces with Clover Trail," said Bryan Korba, Chairman and Chief Executive Officer of Alternate Health. "It is an excellent opportunity for us to grow and increase the effectiveness of Alternate Health Labs, already a leading source of revenue for us and a key part of our strategy to fundamentally advance patient care."

The Company funded the acquisition through an issuance of 4,557,150 common shares, subject to a four-month holding period and an 18 month term note of US$ 1,993,750 payable to one of the sellers. After January 2018, the sellers have an option to put additional ownership of Clover Trail to the Company. Any future sales will be at a price based on a valuation by a mutually agreed independent business valuator.

"This is a winning agreement for both companies," said Dr. Michael Murphy, who indirectly controls Clover Trail Capital and recently completed a Lab Development Agreement with Alternate Health. "Our goal is to make healthcare laboratory services more efficient and costeffective, and with this move we take a major step in that direction."


Contact

Jim Griffiths

Director of Investor Relations

416-607-5757


About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.



ALTERNATE HEALTH CORP. CLOSES LICENSE TRANSACTION WITH SENTAR PHARMACEUTICALS

VANCOUVER, B.C. – March 3, 2017 - Alternate Health Corp. (CSE:AHG) (the "Company" or AHC) is pleased to announce the finalization and closing of its transaction with EFT Global Holdings, d.b.a Sentar Pharmaceuticals ("Sentar"); on March 2, 2017; an exclusive agreement for non-pharmaceutical sublingual delivery of CBD and THC. The transaction was previously announced in the Company's news release disseminated on January 19, 2017. The Company wishes to note a correction to the January 19, 2017 news release pertaining to the issuance of 2,118,500 common shares in various consulting fees. Pursuant to the stipulation in the agreement, the accurate amount is 2,118,506 common shares in consulting fees.


Under to the terms of the agreement, AHC entered into a 10-year renewable license agreement with Sentar, whereby Sentar has agreed to grant AHC a 10 year worldwide license rights to its patented Sublingual Delivery Systems to administer CBD and THC nutraceuticals in tablet form ("Technology"). Consideration paid to Sentar by AHC for the license consists of 850,000 AHC common shares at a deemed price of $1.00 per share plus a royalty on future sales or profits; and 2,118,506 AHC common shares at a deemed price of $1.00 per share for various consulting fees for services rendered in assistance with obtaining the license, the ongoing development and commercialization of the Technology, and assistance in obtaining regulatory approvals and permits for related products. All parties to the license and consulting agreements are at arm's length to the Company.


The Sentar share issuance totalling 2,968,506 is subject to a four month hold.

About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Bryan Korba

CEO and Chairman

For further information, please contact Thomas F. Bartlett at 1.214.906.0684.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.



ALTERNATE HEALTH CORP. APPOINTS NEW DIRECTORS AND OFFICERS OF THE COMPANY

VANCOUVER, B.C. – February 10, 2017 - Alternate Health Corp. (CSE:AHG) (the "Company") is pleased to announce recent appointments to the Company's Board of Directors and Officers of the Company. The following Directors and Officers have been appointed:


Bryan Korba – Chairman and Chief Executive Officer

Bryan has spent the last 17 years as the Managing Partner of JDIFU Capital, a consulting and private equity investment company he co-founded with his late father and mentor, Robert Korba. The company manages the assets and private equity investments of the Korba Family Investment Office. JDFIU Capital has completed over $100 million in investments in varied industries including healthcare, real estate, software, franchising, hospitality, furniture and financial services. Additionally, Bryan has consulted with many CEOs on mergers and acquisitions, strategic planning, corporate development and company culture and governance. Bryan currently serves on the board of Empower Heroes, a charity he cofounded that services veterans and their families as they re-enter civilian life. Bryan previously served on the boards of 36 Power Equity, Luxe Home, Dallas Challenge and the UNT Venture Fund. Bryan earned a MBA in finance from Texas Christian University and a BBA in economics from the University of North Texas and continues to guest lecture on real estate and entrepreneurial ventures.

Michael English – Chief Financial Officer

Mike English has over 30 years' experience working in diverse industries including data security and encryption software, telecommunications, and heavy industrial electric motors and controls. Ten of those years were with a leading software as a service (SAAS) public encryption company where he served as controller and CFO. Under Mike's leadership, the company drastically improved earnings and cash flow while reducing the company's risk profile and improving compliance. They achieved best in class public company audit committee ISS governance ratings. As a Vice President of Finance and Controller in the telecommunications and heavy industrial electric motors and controls industries, Mike managed large groups including director level direct reports in multi-locations, both domestic and international (US, Canada, UK, Germany, Italy and Israel). In addition to accounting and reporting responsibilities, a major part of his role included implementing and integrating enterprise wide software (SAP) across several manufacturing divisions. Over a career that spans auditing, controllership, financial systems and senior executive financial management, Mike's experience reaches across technical accounting, financial reporting and disclosure controls, risk avoidance, multi-location, SEC reporting, public company corporate governance, equity compensation, manufacturing cost accounting and includes HR and benefits, IT, facilities management and strategy. Mike earned a BA in English with a concentration in business from John Carroll University and an MS in Accountancy from DePaul University. He is a CPA and is a member of the Ohio Society of CPA's.

Thomas Bartlett – Chief Operating Officer

Tom Bartlett has over thirty years of private equity, investment banking, corporate advisory, and operating experience. Throughout his career, Tom has financed, advised or served in executive management capacities to drive growth and value appreciation of businesses operating across a spectrum of industries and business models. Prior to joining Alternate Health Corp. as its Chief Operating Officer, Tom served as the President and CFO of an insurance services company where Tom was directly responsible for executing multiple acquisitions and financings for the business in addition to overseeing the overall operational and financial functions of the company. In his capacity of COO at Alternate Health, Tom is primarily responsible for implementing and directing growth and diversification strategies across the AHC platform. Tom has a BBA in finance and management from Baylor University.

Jamison Feramisco – Director

Dr. Jamison Feramisco, MD, PhD, is trained in both Internal Medicine and Dermatology and completed his PhD research thesis in the laboratory of Nobel Laureates Drs. Mike Brown and Joe Goldstein at UT Southwestern Medical Center. He has an extensive history of success in founding, funding, and growing numerous healthcare service and technology companies. Dr. Feramisco is the founder and President of Apri Health (formerly Transfuse Solutions), a next-generation healthcare data analytics and change management company based in Dallas, Texas. He also serves as Chief Medical Officer of both Third Eye Health, a technology-enabled medical services company, and Advanced Healthcare Solutions nursing home chain. His former positions include founder and President of Golden Healthcare of Temecula, California, a medical service corporation specializing in home health care designed with the patient's need for personal care and safety in mind; Chief Medical Officer of Scanadu, a cutting edge wearable device company with headquarters at NASA's Moffitt Field, CA.; co-founder and chief medical officer/chief operating officer of Dermlink, one of the first consumer focused tele-dermatology software companies. He has served on the board of multiple healthcare and technology companies and is an active mentor at many of the Bay Area healthcare incubators. Clinically, Dr. Feramisco focuses primarily on three areas of medicine: 1) Hospitalist Medicine - general medical care of hospitalized patients including patient care, teaching, research and leadership related to hospital medicine; 2) Dermatology, the medical care of the skin and its diseases; and 3) Wound Care, the medical care in the prevention of wound complications and the promotion of wound healing. Dr. Feramisco has a successful track record as an entrepreneur and is a respected Angel Investor and consultant for venture capital and private equity.

Adam Desmond - Director

Adam Desmond began his career at the Chicago Mercantile Exchange in the financial quadrant. He then went on to Raymond James and Associates where he helped develop a high yield fixed income department. This experience gave him the groundwork to found ASG Securities in 1998. There, his vision was to focus exclusively on small/mid-cap banks and thrift markets. In 2004, ASG Securities transformed into FIG Partners LLC. As Founder and one of the Managing Principals, Adam and his team added a research division to expand the business from a sales and trading platform into a full service investment banking firm. This implementation resulted in full research on over 120 banks. Under his leadership, as co-head of Investment Banking, Adam assembled a team of principals at raised more than $2.5 billion in equity since 2007 and completed more than 95 whole bank transactions throughout the United States. Through the trading platform Fig was a market maker in over 800 community banks and thrifts. As Fig's reputation grew, Adam directed the strategy to create both Fixed Income and Corporate Development departments to implement cross selling to Fig's client base. With its headquarters in Atlanta, FIG Partners expanded from one office and a hand full of employees, to offices in Chicago, Los Angeles, San Francisco, Dallas, New Jersey and Charlotte, employing over 60 people. Adam's expertise in the banking sector has brought him into contact with top executives from over 250 banks and thrifts, as well as building close relationships with the foremost institutional equity managers. He also served as a board member for Goldwater Bank in Scottsdale Arizona. Adam recently created Needle Rock Capital to leverage his past expertise in the financial industry and his relationships. In addition, he founded Needle Rock Farms, to explore alternative health solutions. Adam prides himself on being a member of the Elks Club. He enjoys supporting and servicing many charitable organizations. For example, Adam sponsored charitable organizations in India and Laos. Through St. Mary's Catholic Church in Aspen, he helped fund the building of a school in the Philippines. Adam graduated from the University of Wisconsin – Madison with a Bachelor of Arts in International Economics and Political Science.

Marcelin O'Neill – Corporate Secretary and Compliance Officer

Marcelin O'Neill is currently a Director and CEO of Cervantes Capital Corp., and also presently the Compliance Officer and Corporate Secretary of Alternate Health Corp. Ms. O'Neill served as a Director of Jagercor Energy Corp. from December 2011 to May 2014, and as Chief Financial Officer and Corporate Secretary of Jagercor, from July 2013 to May 2014. She served as a director of Brandenburg Energy Corp. from February 2008 to February 2013, and as Chief Financial Officer and Corporate Secretary from August 2010 to February 2013. Ms. O'Neill served as the Vice President of Corporate Affairs of Mandalay Resources Corporation from April 2009 to March 2010, and from April 2007 until May 2008, she served as a director of Mandalay. Since 1994 Ms. O'Neill has worked with such companies as Augusta Resource Corporation, Westcoast Energy Inc., and the Lundin Group. In 1987, Ms. O'Neill graduated from the British Columbia Institute of Technology, where she studied Business Management, and has successfully completed the CSC and the CPH, both with honors. Ms. O'Neill is the managing director of Accrete Consulting Inc., a company which provides corporate governance and management services to public companies. With over 23 years of experience in public company management, Ms. O'Neill brings a varied scope of knowledge to the companies with which she works.

Resignations

The Company wishes to announce that the following individuals have tendered their resignations to the respective roles as indicated: Marjorie Sanderson resigned as Director and Chief Executive Officer, Jim Griffiths resigned as Chief Financial Officer, Marcelin O'Neill resigned as a Director of the Company; and Rick Macartney resigned as a Director of the Company. Alternate Health would like to thank Ms. Sanderson, Mr. Griffiths, Ms. O'Neill, and Mr. Macartney for their assistance while serving in the aforementioned roles.

The Board of Directors is now comprised of Bryan Korba, Jim Tykoliz, Jim Griffiths, Jamison Feramisco and Adam Desmond.

"This is the right time for Bryan and his incoming team to lead Alternate Health into the next chapter of our company's exciting future. Bryan brings a unique combination of entrepreneurial experiences with a dedication to creating and executing dynamic strategic plans. His vision, strategy and execution track record is exactly what Alternate Health needs at this point of rapid growth and market expansion. I am confident in the strong leadership that Bryan will bring to our company and know he will energize and inspire our employees, shareholders, customers and partners," said Alternate Health Director Jim Griffiths.

About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

"Bryan Korba"

Chairman and CEO

For further information, contact Jim Griffiths at 416-607-5757.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.


SOURCE Alternate Health Corp.

To view this news release in HTML formatting, please use the following URL:

https://www.newswire.ca/en/releases/archive/February2017/10/c7695.html

%SEDAR: 00037135E

For further information: contact Bryan Korba at info@alternatehealth.ca

CO: Alternate Health Corp.

CNW 17:12e 10-FEB-17


ALTERNATE HEALTH CORP. ANNOUCES CONSULTING AGREEMENT

VANCOUVER, B.C. – January 31, 2017 - Alternate Health Corp. (CSE:AHG) (the "Company") is pleased to announce that that it has entered into a consulting agreement with a consultant of the Company for the purposes of compliance and regulatory filings. Pursuant to the terms of the consulting agreement, the Company will issue 50,000 common shares to the consultant for past services rendered.


About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths

Director and CFO

For further information, contact Jim Griffiths at 416-607-5757.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.


Alternate Health Corp. Provides Update on CBD Patented Delivery Systems and First Day of Trading

VANCOUVER, B.C. – January 25, 2017 - Alternate Health Corp. (CSE:AHG)(the "Company") wishes to expand on its previously announced transdermal patch and non-pharmaceutical sublingual dissolvable tablet delivery systems being licensed under its Medipatch and Sentar agreements. These patented delivery systems represent a safe and controlled method for delivering measured doses of pharmaceutical grade CBD and THC based medicines. The Medipatch and Sentar Agreements are expected to close in the next two weeks.

While terms of the Agreements provide for long-term product development and commercialization, the immediate opportunity to manufacture and distribute proprietary products in the US, Canada and the United Kingdom represent significant revenue generating businesses for Alternate Health for many years to come."These patents allow Alternate Health to specifically control dosages and provide a safe, medically viable delivery system for cannabis and CBD's," said Jim Griffiths, CFO for Alternate Health. "This furthers the Company's plans to become an international leader in cannabis derived medicines."

Under the previously announced pending Alturas Joint Venture Agreement, an existing building on sovereign Native American land in northern California will be used as a research and testing facility. It will also include a CBD extraction and refinement plant expected to be operational this spring. Alternate Health is also currently in discussions with several Canadian LP's (licensed providers) for manufacturing and delivering its patented products and delivery systems in the Canadian market.

According to USA Today, the California marijuana Industry is estimated to grow to $25 billion annually, and is set to eclipse $50 billion by 2026. "Alternate Health is uniquely positioned for licensing their manufacturing pharmaceutical grade delivery systems of CBD and THC healing products in this fast-growing new marketplace," said Jim Tykoliz, Director of New Ventures, Alternate Health. "It is Alternate Health's intentions to provide organic, safe and healthy medicines through our patented delivery systems to patients around the world, and the California market represents a significant starting point for us."


Successful First Day of Trading

On January 24th, 2017, the Company's first day of trading on the Canadian Securities Exchange, Alternate Health's shares opened at $3.28, traded at a high of $3.50, at a low of $3:15, and closed at $3.28; on volume of 44,300 shares.

Consulting Agreement

About Alternate Health Corp.

Alternate Health (https://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths

Director and CFO

For further information, contact Jim Griffiths at 416-607-5757.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.


ALTERNATE HEALTH CORP. ANNOUNCES PRIVATE PLACEMENT OFFERING

VANCOUVER, B.C. – January 24, 2017 – Alternate Health Corp. (the "Company" or AHC) announces that the Company will complete a non-brokered private placement of up to 3,000,000 common shares at a price of $3.25 per common share for aggregate gross proceeds of up to $9,750,000. The Company may pay finder's fees as permitted by applicable securities laws and the policies of the CSE.


Joint Venture Agreement with Alturas Indian Rancheria

The Company is also pleased to announce that it has entered into an agreement with Alturas Indian Rancheria ("Alturas") to form a Joint Venture Company where ownership in the venture will be 55% Alturas and 45% AHC. The Agreement provides that Alturas and AHC, or its subsidiary, enter into a 30 year land lease (including all buildings) on a 10 acre site, owned by Alturus. A new CBD Testing and Research Facility is intended to be constructed on this land, with a focus on furthering research and development in the use of Cannabidiol for medical and therapeutic treatments. California is the world's largest medical marijuana market and will soon open the market for recreational sales this year, with this Agreement expected to strongly position AHC to become a market leader.

AHC will issue 1,500,000 common shares to Alturas upon closing of the transaction, with a potential additional 1,500,000 common shares of the Company to be issued at a future date, for the expansion of the business, subject to approvals by both parties. The Agreement further provides that AHC annually grant warrants to Alturus, to purchase 100,000 common shares of the Company, for each year the Joint Venture is in operation, which is estimated to be 30 years. Each warrant grant will expire one year from the date of the grant, and the warrant exercise price will be set in accordance with the Canadian Securities Exchange polices and securities regulations.

Consulting Agreement

The Company is pleased to announce that it has entered into a consulting agreement with a US-based consultant effective January 23, 2017 for the purposes of delivering hospital relationships for the Company's business objectives. Pursuant to the terms of the consulting agreement, the Company will issue 250,000 common shares, which will be subject to escrow. The release of the escrowed shares will be subject to certain performance conditions.

About Alternate Health Corp.

Alternate Health is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health Corp. is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health Corp. offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs.

Alternate Health Corp.'s goal is to continue to lead the medical industry with data-driven results in patient care and product development.

On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths Director and CFO

For further information, contact Jim Griffiths at 416-607-5757.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements. There are no assurances that the agreements and transactions described in this news release will close.


ALTERNATE HEALTH CORP. ANNOUNCES PRIVATE PLACEMENT OFFERING

VANCOUVER, B.C. – January 20, 2017 – Alternate Health Corp. (the "Company" or AHC) announces that the Company will complete a non-brokered private placement of up to 3,000,000 common shares at a price of $3.25 per common share for aggregate gross proceeds of up to $9,750,000. The Company may pay finder's fees as permitted by applicable securities laws and the policies of the CSE.

The Company intends to use the proceeds of the private placement for commercialization of its recently acquired CBD delivery system licenses, expansion of its toxicology laboratory business acquired in January and for targeted revenue generating acquisitions in the health care industry.

The Company's common shares are listed on the CSE under the symbol "AHG" and trading will commence on January 24, 2017.


On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths

CFO and Director, Alternate Health Corp.

For further information, contact Jim Griffiths at 416-607-5757.

About Alternate Health

Alternate Health is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health Corp. is a leader in software applications and processing systems for the medical industry using proprietary technology platforms.

Through its subsidiaries, Alternate Health Corp. offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health Corp.'s goal is to continue to lead the medical industry with data-driven results in patient care and product development.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements. There are no assurances that the financing described in this news release will close or will close for the amount announced.


ALTERNATE HEALTH CORP. RAISES $4.37 MILLION IN PRIVATE PLACEMENT AND ANNOUNCES CSE LISTING

VANCOUVER, B.C. – January 19, 2017 – Alternate Health Corp. (the "Company" or AHC) is pleased to announce that the Company has received subscription agreements totaling gross proceeds of $4,371,530.50 following closing-off sales of its current private placement offering at $1.50 per common share. The offering was over-subscribed by $371,530.50, for the total issuance of 2,914,354 common shares. Formal closing of the private placement will occur tomorrow. Finder's fees of $378,720.15 will be paid to Mackie Research Capital Corporation as permitted by CSE policies and applicable securities laws. All common shares issuable under the private placement will have a four month hold period in accordance with securities laws.

AHC is pleased to announce that today, the Canadian Securities Exchange issued its Bulletin announcing the Company's listing on the CSE, with trading commencing on January 24, 2017 under the symbol "AHG". Please refer to the link below to access the CSE Bulletin. CLICK HERE TO READ BULLETIN

Agreement to acquire 20% of Clover Trail Capital LLC

Clover Trail Capital LLC, ("Clover") a Texas-based limited liability company, owns approximately 40% of Sun Clinical Laboratories LLC, which refers toxicology samples to AHC subsidiary Alternate Health Labs Inc. including samples directed by Paradigm Health Solutions LLC. The arm's length acquisition price of US $5,500,000 was based on Clover's past and forecasted revenues and will be settled with 4,557,150 AHC common shares at an agreed price of $1.00 per share and an 18 month term note for US $1,993,750 payable to the seller. The transaction is expected to close in early February. Clover is indirectly controlled by Dr. Michael Murphy who recently completed a Lab Development Agreement with AHC.

10-year renewable license agreement with EFT Global Holdings

EFT Global Holdings / Sentar Pharmaceuticals has agreed to grant AHC 10 year worldwide license rights to its patented Sublingual Delivery Systems to administer CBD and THC nutraceuticals in tablet form ("Technology"). Consideration for the license is 850,000 AHC common shares at an agreed price of $1.00 plus a royalty on future sales or profits.

In addition, the Company agreed to pay consulting fees in the form of 2,118,500 AHC common shares at an agreed price of $1.00 per share for services rendered for assistance in obtaining the license, the ongoing development and commercialization of the Technology and assistance in obtaining regulatory approvals and permits for related products. All parties to the license and consulting agreements are arm's length. These transactions are expected to close in February.

Agreement to purchase transdermal medical patch technology

AHC has agreed to acquire from Dr. James Williams ("Williams") provisional patent #2016-0361271-A1, proprietary transdermal patch technologies, and certain assets owned by Medipatch Inc, a company controlled by Williams. When applied to the skin, the transdermal patch is capable of transferring active pharmaceutical or nutraceutical ingredients via the skin and into the body.

Under the agreement, Williams will receive 150,000 AHC common shares, 50,000 on closing and 100,000 when the technology and certain assets are transferred to AHC. The agreement also provides that Williams be granted warrants to acquire 25,000 AHC common shares at a purchase price of $3.35 per common share for a period of 18 months from closing which is expected to occur on or before February 8, 2017. On closing Williams or an affiliate will sign a management agreement with AHC to operate the commercial business using the technology and the acquired assets that will compensate Williams with a monthly retainer and a royalty from sales or profits generated from the Medipatch assets and intellectual Property acquired from Williams.

Agreements for further consulting services

The Company has also signed consulting services agreements with five individuals, for cash, shares and warrants including aggregate share compensation of 562,650 AHC common shares and 180,000 warrants to acquire AHC common shares at $1.00 per share for an 18-month period ending July 8, 2018. The consulting services include: Ongoing research, product development and manufacturing support related to newly licensed technologies, general management services for the Company's Continuing Medical Education Business, legal services, consulting related to sourcing new customers for the Company and business acquisition opportunities.


For further information, contact Jim Griffiths at 416-607-5757 . On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths

CFO and Director, Alternate Health Corp.

About Alternate Health

Alternate Health is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health Corp. is a leader in software applications and processing systems for the medical industry using proprietary technology platforms.

Through its subsidiaries, Alternate Health Corp. offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health Corp.'s goal is to continue to lead the medical industry with data-driven results in patient care and product development.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements. There are no assurances that the agreements and transactions described in this news release will close.


ALTERNATE HEALTH CORP. CLOSES THREE KEY AGREEMENTS PRIOR TO CSE LISTING

VANCOUVER, B.C. – January 13, 2017 – Alternate Health Corp. (the "Company" or AHC) is pleased to announce the finalization of three key agreements to strengthen the Company's position in the medical education and laboratory testing market.

These agreements further AHC's goal of improving patient care and outcomes by acquiring assets and exclusive rights to new research and technologies. The details for each agreement are listed below.


Acquisition of Alternate Health Labs Inc.

AHC has closed the Lab Development Agreement with Dr. Michael Murphy ("Murphy") with the acquisition of Alternate Health Labs Inc. ("AHL") for consideration of 1,920,000 common shares of AHC at the previously agreed price of $1.00 per share.

AHL operates a 17,000 sq ft toxicology laboratory in San Antonio, Texas, with current testing equipment capacity to process up to 70,000 urine and blood samples per month and sufficient space to double its processing capacity. LMK Management LLC, a company controlled by Murphy, will continue to manage AHL's toxicology laboratory business.


Cooperation and Consulting Agreement with Paradigm Health Solutions

AHC and Paradigm Health Solutions LLC ("Paradigm") have agreed on a mutual cooperation and consulting agreement with the issue of 1,500,000 common shares of AHC at the previously agreed price of $1.00 per share. Paradigm is an aggregator of toxicology samples and under the Consulting Agreement it has agreed to direct all of its toxicology and blood samples to AHL via Sun Clinical Laboratories LLC, an entity indirectly controlled by Murphy.

AHC shares are being held in escrow and will be released in tranches as Paradigm achieves agreed sample delivery targets of up to 150,000 samples per month and/or signs four hospital contracts for the benefit of Paradigm and AHL.


Exclusive Rights to Medical Cannabis Education, Patents and Research

AHC is issuing 350,000 AHC common shares to Dr. Michelle Reillo as partial consideration for granting AHC and its subsidiaries the exclusive rights to commercialize her American Medical Association approved continuing medical education course on the use of medical Cannabis as well as rights to certain patents and ongoing research related to medical cannabis.


Private Placement and CSE Listing

The Company has filed its CSE Form 2A Listing Statement dated January 12, 2017 and the Listing Statement contains additional details of the key agreements described above. The Company expects that its previously announced $4 million private placement will be fully subscribed and will close coincident with the CSE Listing Bulletin expected next week./p>

For further information, contact Jim Griffiths at 416-607-5757. On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths

CFO and Director, Alternate Health Corp.

About Alternate Health

Alternate Health is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health Corp. is a leader in software applications and processing systems for the medical industry using proprietary technology platforms.

Through its subsidiaries, Alternate Health Corp. offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health Corp.'s goal is to continue to lead the medical industry with data-driven results in patient care and product development.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.


ALTERNATE HEALTH CORP. RECEIVES RECEIPT FOR PROSPECTUS AND CONDITIONAL APPROVAL TO LIST SHARES ON CSE

Vancouver, BC, December 23, 2016 – Alternate Health Corp. (the "Company" or "AHC") is pleased to announce that it has filed and obtained a receipt from the Ontario Securities Commission dated December 5, 2016 for its Final Non-Offering Prospectus ("Prospectus") dated November 29, 2016. A copy of the Prospectus is available on SEDAR under the Company's profile at www.sedar.com.

The Company has also received conditional approval from the Canadian Securities Exchange (the "CSE") for the listing of its common shares on the CSE subject to the completion of customary requirements of the CSE, including the receipt of all required documentation. Once final approval is received, the common shares of AHC will commence trading under the trading symbol: AHG.

The Company announces that it has completed a share exchange (the "SEA") with the securityholders of Alternate Health Inc. ("AHI"). A total of 32,519,636 common shares were issued to former AHI shareholders under the SEA and 606,250 replacement warrants. The replacement warrants all have an exercise price of $1.50 and expire in March, September, and October 2017, respectively. AHI is now a wholly-owned subsidiary of the Company and the business of AHI is the Company's principal focus. Following the closing of the SEA, the Company has 32,916,236 outstanding common shares.

The Company also wishes to announce a private placement for gross proceeds up to $4,000,000. The Company will issue up to 2,666,667 common shares at a price of $1.50 per common share. All common shares issued under the private placement will be subject to a 4 month hold period. The Company may pay finder's fees in accordance with applicable securities laws.

For further information, contact Jim Griffiths at 416-607-5757.


On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths

CFO and Director, Alternate Health Corp.

About Alternate Health

Alternate Health is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.


ANNUAL GENERAL MEETING

Vancouver, BC, May 27, 2016 – Alternate Health Corp. (formerly 1017344 B.C. LTD.) ("Alternate" or the "Company"). wishes to announce that all of the resolutions put forth at the Company's Annual General Meeting of Shareholders held on May 26, 2016 have been approved.

In addition to the standard annual shareholder resolutions which include setting the number of directors, the election of the directors of the Company, and the appointment Scarrow Yurman & Co., Chartered Professional Accountants, as auditors for the coming year, the Company's shareholders approved and ratified the Company's 15% rolling stock option plan. A majority of votes cast, by disinterested shareholders, was received on this resolution.

At the meeting the following directors were elected; and directly after the meeting the Board of Directors appointed the following Officers:

Directors:
Bobby Curtola
James Tykoliz
Rick Macartney
Marcelin O'Neill
Marjorie Sanderson
Jim Griffiths

Officers:
Bobby Curtola, Chairman
Marjorie Sanderson, Chief Executive Officer
Jim Griffiths, Chief Financial Officer
Marcelin O'Neill, Corporate Secretary

About Alternate

Alternate is a reporting issuer, duly incorporated in the Province of British Columbia, currently seeking a listing on the Canadian Securities Exchange.

For further information on Alternate, please contact:

Alternate Health Corp.
Bobby Curtola
Director & Chairman
Telephone: +1.902.809.4243
Email: b.curtola@gmail.com


ALTERNATE HEALTH CORP. AGREES TO COMPLETE SHARE EXCHANGE WITH ALTERNATE HEALTH INC.

Vancouver, British Columbia –November 27, 2015 – Alternate Health Corp. (the "Company" or "AHC") is pleased to announce that it has agreed to the terms of a share exchange agreement (the "Share Exchange Agreement") with Alternate Health Inc. ("AHI") to complete the proposed acquisition of AHI.

AHI is a privately held, Ontario company formed as a medical services company in the Canadian market with interest in promoting both traditional (i.e. physicians) and non-traditional (i.e. chiropractors, Naturopaths) solutions to modern healthcare. AHI has one wholly-owned subsidiary, CanaCard Inc., also an Ontario company. AHI holds exclusive licenses in Canada for the VIP-Patient Electronic Medical Records platform and the CanaCard Controlled Substances Patient Management System.

The transaction will be carried out as a share exchange (the "Share Exchange") pursuant to which, among other things: (i) AHC will acquire all of the issued and outstanding shares of AHI, and AHI will become a wholly-owned subsidiary of AHC; (ii) shareholders of AHI will be issued one common share of AHC for every one common share of AHI held at the effective time of the Share Exchange; and (iii) warrant holders of AHI will be issued warrants of AHC on equivalent terms as, and in replacement of, all outstanding AHI warrants, and the AHI warrants will be cancelled.

Completion of the Share Exchange remains subject to a number of conditions, including but not limited to, satisfaction of standard closing conditions for transactions of this nature. The Company intends to apply for listing on the Canadian Securities Exchange as part of completion of the Share Exchange.

ON BEHALF OF THE BOARD

"Bobby Curtola"

Director and Chairman

For further information contact:

Alternate Health Corp.
Bobby Curtola
Director & Chairman
Telephone: +1.902.809.4243
Email: b.curtola@gmail.com

This news release is not an offer of securities of the Company for sale in the United States. The above described issuances of securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration. This news release shall not constitute an offer to sell or solicitation of an offer to buy nor shall there by any sale of the above described securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Disclaimer for Forward-Looking Information:

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the proposal by the Company to complete the Share Exchange, issuances of securities thereunder and associated transactions, including statements regarding the terms and conditions of the Share Exchange Agreement and AC/3680132.1 statements regarding AHI's business, products and future plans. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the parties will not complete the Share Exchange and associated transactions for any reason, that the ultimate terms of the Share Exchange and associated transactions will differ from those that currently are contemplated, and that AHI's products and plan will vary from those stated in this news release and that AHI may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. The statements in this press release are made as of the date of this release.

AC/3680132.1


ALTERNATE HEALTH CORP. APPOINTS DIRECTOR AND CHIEF FINANCIAL OFFICER

Vancouver, BC, September 8, 2015 – Alternate Health Corp. (formerly 1017344 B.C. LTD.) ("Alternate" or the "Company"). Alternate is pleased to announce the appointment of Jim Griffiths as Chief Financial Officer, and to the Company's Board of Directors.

Mr. Jim Griffiths is a current member of the Board of Trustees of the Center for Addiction and Mental Health ("CAMH") in Toronto, Jim has a Masters in Business Administration, is a chartered accountant, and has over 30 years of experience in the real estate development/financing industries. He was the Vice President Finance of Genstar Property Corporation and the President of First City Development Corp. He was also President and director of RealFund, Canada's first public Real Estate Investment Trust and Krystal Bond Inc. During his career, he has had responsibility for real estate asset acquisitions and sales of over $2 billion. In addition he is very experienced in financing real estate and has negotiated and placed real estate loans in an amount exceeding $2.5 billion.

Jim was a past director of Pinetree Capital Inc., the Canadian Institute of Public Real Estate Companies and was the Founding Chairman of the Association of Foreign Investors in U.S. Real Estate. He is currently a director of Allied Properties Real Estate Investment Trust, Enssolutions Group Inc., and Champion Partners and is President of KLC Capital Investment Corporation, which provides financial advisory services.

About Alternate

Alternate is a reporting issuer, duly incorporated in the Province of British Columbia, currently seeking a listing on the Canadian Securities Exchange.

For further information on Alternate, please contact:

Alternate Health Corp.
Bobby Curtola
Director & Chairman
Telephone: +1.902.809.4243
Email: b.curtola@gmail.com


ALTERNATE HEALTH CORP. APPOINTS BOARD OF DIRECTORS AND OFFICERS OF THE COMPANY

Vancouver, BC, May 29, 2015 – Alternate Health Corp. (formerly 1017344 B.C. LTD.) ("Alternate" or the "Company"). Alternate is pleased to announce recent appointments to the Company's Board of Directors and its Officers.

Bobby Curtola – Director and Chairman

As an icon of the Canadian Music Industry, Bobby Curtola ranks among the most decorated artists of all time, with 25 gold records and many year of touring internationally. Mr. Curtola is also involved in many North American charities and has hosted numerous telethons coast to coast in Canada every year including charitable work in Indonesia, Bulgaria, Ecuador and the USA. In 1998, Mr. Curtola was made a Certified Member of the Order of Canada in recognition of his long service to the Canadian Music Industry as well as his humanitarian work around the world.

Marjorie Sanderson – Director and Chief Executive Officer

Ms. Sanderson graduated from the Hospital for Sick Children as a Registered Nurse, and was team leader in 1970 with a specialty in the treatment of burns in children with learning disabilities. Ms. Sanderson worked in the medical sector as a registered nurse until 1997. Since 1976, Ms. Sanderson has worked as a Canadian Tax Consultant working with trusts, corporate and personal taxes; and is owner of the accounting firm, Partners Income Tax Services, a wholly owned division of Templus Inc. Ms. Sanderson taught stress management at the University of Toronto, and from 1972 to 1984, also taught tax accounting for the CGA. Since 2011 Ms. Sanderson has served as a member of the Women's International Leadership Association.

Rick Macartney - Director

Rick Macartney has over 25 years in both senior management and consulting roles, assisting a wide variety of businesses to profitability, develop strategic and financial plans, re-organize and streamline operations, and develop new businesses. With both Bachelor's and Master's degrees in Economics, Mr. Macartney has accomplished many assignments in a wide variety of both large and small businesses. For the past nine years he has consulted with private clients in markets as diverse as entertainment, real estate, solar energy, and other sectors.

James E. Tykoliz – Director

Building on his degrees in Finance & Economics from the University of Western Ontario, Mr. Tykoliz managed large accounts for pharmaceutical and packed goods companies for A.C. Nielsen Market Research before becoming an entrepreneur and building and managing dot.com operations. Mr. Tykoliz brings Alternate Health over 27 years of sales solutions and client oriented service experience in data driven, financial service environments.

Marcelin O'Neill – Director and Corporate Secretary

Ms. O'Neill served as a director of Jagercor Energy Corp. from December 2011 to May 2014, and as Chief Financial Officer and Corporate Secretary of Jagercor, from July 2013 to May 2014. She served as a director of Brandenburg Energy Corp. from February 2008 to February 2013. Ms. O'Neill was appointed as the Vice President of Corporate Affairs of Mandalay Resources Corporation from April 2009 to March 2010, and from April 2007 until May 2008, she served as a director of Mandalay. Since 1994 Ms. O'Neill has worked with such companies as Augusta Resource Corporation, Westcoast Energy Inc., and the Lundin Group. In 1987, Ms. O'Neill graduated from the British Columbia Institute of Technology, where she studied Business Management, and has successfully completed the CSC and the CPH, both with honours. Ms. O'Neill is the managing director of Accrete Consulting Inc., a company which provides corporate governance and management services to public companies. With over 21 years of experience in public company management, Ms. O'Neill brings a varied scope of knowledge to the companies with which she works.

About Alternate

Alternate is a reporting issuer, duly incorporated in the Province of British Columbia, currently seeking a listing on the Canadian Securities Exchange.

For further information on Alternate, please contact:

Alternate Health Corp.
Bobby Curtola
Director & Chairman
Telephone: +1.902.809.4243
Email: b.curtola@gmail.com


ALTERNATE HEALTH CORP. (FORMERLY 1017344 B.C. LTD.) COMPLETES A PLAN OF ARRANGEMENT WITH RISKE CAPITAL CORP.

Vancouver, BC, April 24, 2015 – Alternate Health Corp. (formerly 1017344 B.C. LTD.) ("Alternate"). Alternate is pleased to announce that it has completed a statutory arrangement under a Plan of Arrangement (the "Arrangement") among Alternate and Riske Capital Corp. ("Riske"). As a result of completing the Arrangement, Alternate became a reporting issuer in Alberta and British Columbia.

On October 29, 2014, Riske and Alternate, entered into an Arrangement Agreement and Plan of Arrangement (the "Arrangement Agreement").

Completion of the Arrangement as set forth in the Arrangement Agreement was approved by the shareholders of Riske and 1017344 B.C. LTD. on December 1, 2014; and a final order granted by the Supreme Court of British Columbia on December 3, 2014 in accordance with Part 9 of the Business Corporations Act (British Columbia).

By approval of the Board of Directors of Riske, upon the Arrangement becoming effective on April 15, 2015, Alternate became a reporting issuer in the jurisdictions of Alberta and British Columbia. The CUSIP for the Common Shares of Alternate is 02090B102.

Alternate was incorporated on October 26, 2014 and its fiscal year end is December 31. 1017344 B.C. Ltd. changed its name to "Alternate Health Corp." on April 16, 2015.

About Riske:

Riske is a business development services company. It provides business development services to new and emerging businesses, including making introductions to accountants, lawyers, brokers, transfer agents, and various other professionals and service providers to assist companies in raising capital and going public. It also advises companies on corporate structure and in business development, including seeking and advising on opportunities in mergers and acquisitions. It intends to take our compensation through a combination of securities and monetary fees.

For further information on Alternate, please contact:
Alternate Health Corp.
Howard Mann
Chief Executive Officer
Telephone: 1.310.926.2141
Email: hmann@dcnetcast.com

For further information on Riske, please contact:
Riske Capital Corp.
Dustin Riske
Chief Executive Officer
Telephone: 604.724.6362
Email: dustin@bullandbearwealth.com

Disclaimer for Forward‐Looking Information. Statements in this press release regarding Riske and Alternate which are not historical facts are "forward‐looking statements" that involve risks and uncertainties. Such information can generally be identified by the use of forward‐looking wording such as "may", "will", "expect", "estimate", "anticipate", "intend", "believe" and "continue" or the negative thereof or similar variations. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated in such statements due to many factors. Except as required by law, Riske and Alternate do not intend to update any changes to such statements. Although management of each company believes that the expectations represented in such forward‐looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such.